

January 29, 2015

CURRICULUM VITAE

Name: Marjorie Robert-Guroff, Ph.D.

Education:

1961-1965 - B.S. (Biology), College of William and Mary, Williamsburg, Virginia

1966-1971 - Ph.D. (Biology), Georgetown University, Washington, DC

Brief Chronology of Employment:

1965-1966 - Biologist, Immunology Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland

1971 - Scientist, Litton Bionetics, Inc., Bethesda, Maryland

1971-1973 - Fellow, Leukemia Society of America, Inc., Laboratory of Tumor Cell Biology (LTCB), NCI, NIH, Bethesda, Maryland

1973-1974 - Fellow, Friedrich Miescher-Institut, Basel, Switzerland

1974-1976 - Scientist II, Litton Bionetics, Inc., Bethesda, Maryland

1976-1980 - Cancer Expert, LTCB, NCI, NIH, Bethesda, Maryland

1980-1983 - Scientist III, Litton Bionetics, Inc., Kensington, Maryland

1983-1986 - Biologist, LTCB, NCI, NIH, Bethesda, Maryland

1986-1993 - Research Biologist, LTCB, NCI, NIH, Bethesda, Maryland

1993-Date - Chief, Section on Immune Biology of Retroviral Infection, VB, NCI, NIH, Bethesda, Maryland

2005-Date – Senior Biomedical Research Service, NIH, Bethesda, Maryland

Societies:

American Association for the Advancement of Science

American Association for Cancer Research

American Society for Biochemistry and Molecular Biology

American Society for Microbiology

International AIDS Society

American Association of Immunologists

Honors and Other Special Scientific Recognition:

Alpha Lambda Delta, College of William and Mary, Virginia, 1962

Mortar Board, College of William and Mary, Virginia, 1965

NASA Predoctoral Traineeship, Georgetown University, Washington, DC, 1966-1971

Sigma Xi, Georgetown University, Washington, D.C., 1970

Fellow, Leukemia Society of America, Inc., NIH, Bethesda, Maryland, 1971-1973

Fellow, Friedrich Miescher-Institut, Basel, Switzerland, 1973-1974

NCI, DBS Intramural Research Award 1997
 Technology Transfer Awards, 1992, 1993
 Federal Technology Transfer Awards - 1994, 1995, 1997-2005, 2007, 2008, 2010, 2011, 2013, 2014
 NIH Undergraduate Scholarship Program Recognition Award, 2005
 Omicron Delta Kappa, College of William & Mary, 2005
 Research Affiliate, Washington National Primate Research Center, 2008
 Elected AAAS Fellow, November, 2011

Invited Talks, Meetings Organized or Chaired:

Retrovirus and Blood Transfusion Workshop Speaker, American Red Cross and the International Society of Blood Transfusion, Washington, DC, 1985.
 AIDS Antiviral Agent Workshop Speaker, NIH, Bethesda, MD 1985.
 American Society for Microbiology, Annual Meeting Speaker, Atlanta, Georgia, 1986
 George Washington University Medical Center Seminar, Department of Biochemistry, 1986
 St. Lukes Hospital Medical Grand Rounds Seminar, Bethlehem, Pennsylvania, 1986
 Georgetown University Seminar, Department of Biology, Washington, DC, 1986
 Laboratory Centre for Disease Control Seminar, Health and Welfare, Ottawa, Canada, 1987
 American Society for Microbiology Annual Meeting, Indianapolis, Indiana, ASM Foundation Lecturer, 1988
 American Society for Microbiology, Texas Branch, Spring Meeting, San Antonio, Texas, ASM Foundation Lecturer, 1988
 Kumamoto University Medical School Seminar, Kumamoto, Japan, 1989
 Cambridge Healthtech Institute Speaker, Vaccines: New Technology and Applications, Washington, DC, 1992
 Ohio Wesleyan University Howard Hughes Program Seminar, Delaware, Ohio, 1994
 Fourth Workshop on Viral Resistance Speaker, Annapolis, Maryland, 1995.
 Scientific Program Committee for Basic Science, the XIth International Conference on AIDS, 1995
 IBC Third Annual Conference on Vaccines: New Advances in Technologies and Applications Speaker, Rockville, Maryland, 1996
 FDA-CBER Seminar, Bethesda, Maryland, 1996
 NCI HIV AIDS Vaccine Meeting, Bethesda, Maryland, 1997
 National Action Plan on Breast Cancer Workshop on Viruses and Human Breast Cancer, Bethesda, MD, Co-Chairperson and Speaker, 1997
 NIAID, LMM Seminar, Bethesda, Maryland, 1998
 Virus Vectors for AIDS Vaccines Workshop Speaker, Palm Springs, CA, 1998
 Workshop on Primate Evaluations of AIDS Vaccine Approaches Speaker, Bethesda, MD, 1998
 Institute for Virus Research Seminar, Kyoto University, Kyoto, Japan, 1998
 Vaccine Research Center Discussion Group Seminar, NIH, Bethesda, MD, 1998.
 Tel Aviv University Seminar, Tel Aviv, Israel, 1998.
 Virology Interest Group Seminar, NIH, Bethesda, MD, 1998.
 Scientific Consultation on Pathogenic HIV Challenge Model for Vaccine Development,

Speaker, NIAID, Bethesda, MD, 1999.

Workshop on Italy-US Concerted Action for the Development of a Vaccine Against AIDS, Istituto Superiore di Sanita, Rome, Italy, 1999. Co-organizer and Speaker.

Vaccines Planning Group for Fiscal Year 2002, Office of AIDS Research, Tysons, Corner, VA, Invited Participant, 2000.

NCI, HAMB Seminar, Bethesda, Maryland, 2000.

Interagency HIV Vaccine Collaborative Group Speaker, NIH Intramural HIV/AIDS Vaccine Program, Bethesda, MD, 2000.

AIDS Vaccine Research Committee Speaker, NIH, Bethesda, MD, 2001.

Pre-IRTA Seminar Series, NIH, Bethesda, MD, 2001.

Second AIDS Seminar Speaker, Kumamoto University, Kumamoto, Japan, 2001.

Institute for Virus Research Seminar, Kyoto University, Kyoto, Japan, 2001.

Vaccine Research Center Seminar, NIH, Bethesda, MD, 2001.

Center for AIDS Research Seminar at the Aaron Diamond AIDS Research Center, New York, NY, 2002.

NIAID, Post-Challenge Evaluations in NHP Models Meeting, Bethesda, MD, Invited Participant, 2002.

Symposium on Viral Regulatory and Accessory Genes for AIDS Vaccine Development, NIH, Bethesda, MD, 2002, Organizer and Speaker.

NCI, BRL, Human Retrovirus Lab Seminar, Frederick, MD 2002.

Gen Star Therapeutics Seminar, San Diego, CA, 2002.

Collaborative HIV/AIDS Vaccine Program Speaker, Istituto Superiore di Sanita, Rome, Italy, 2002.

HIV and Cancer Virology Faculty and Vaccine Working Group Seminar, Bethesda, MD, 2003.

Weill Medical College, Cornell University, Visiting Professor Seminar Series, New York, NY, 2003.

HIV Vaccine Trials Network Full Group Meeting, Plenary Speaker, Bethesda, MD, 2003.

Georgetown University Seminar, Department of Biology, Washington, D.C., 2003.

Third Annual Dawn B. Marks Memorial Research Conference Keynote Speaker, Temple University School of Medicine, Philadelphia, PA 2003.

Division of Viral Products, CBER Seminar, Bethesda, MD, 2004.

NIAID AIDS Vaccine Research Working Group, Persistent Vector Workshop, Bethesda, MD, Invited Speaker, 2005.

NCI, HAMB Seminar, Bethesda, MD, 2005.

NCI Immunology Faculty Seminar, Bethesda, MD, 2005.

Weill Medical College, Cornell University, Visiting Professor Seminar Series, New York, NY, 2005.

Keystone Symposium on HIV Vaccines: Current Challenges and Future Prospects, Invited Speaker, Banff, Alberta, Canada, 2005.

HIV Vaccine Trials Network Full Group Meeting, Plenary Speaker, Washington, D.C. 2005.

2005 International Meeting of the Institute of Human Virology, Baltimore, MD, Invited Speaker, 2005.

23rd Annual Symposium on Nonhuman Primate Models for AIDS, Portland, OR, Invited Speaker and Chairperson, 2005.

Dana Farber Cancer Institute Seminar, Harvard Medical School, Boston, MA 2005.
Department of Cell Biology and Molecular Genetics Seminar, University of Maryland, College Park, MD, 2005.
Istituto Superiore di Sanita, Rome, Italy, Invited Talk and Meeting Participant, 2006.
NIAID, NIH/CBER, FDA Workshop on “Antibodies for the prevention and treatment of poxviral infections,” Invited Speaker, Bethesda, MD, 2006.
ISS/NIH Collaboration Program 2006 Meeting, Rome, Italy, Invited Speaker, 2006.
The 5th International Symposium on Immunological Correlates of Protection from HIV Infection and Disease. Volendam, The Netherlands, Invited Speaker, 2006.
AIDS Vaccine 2006 Meeting, Amsterdam, The Netherlands, Invited Speaker, 2006.
2006 International Meeting of the Institute of Human Virology, Invited Speaker, 2006.
NCI Immunology Faculty Seminar, 2006.
NIAID AIDS Vaccine Working Group, Adenoviral Vector Workshop, Invited Speaker, 2007.
International Workshop on Viruses, Genes and Cancer, Venice, Italy, Invited Speaker, 2007.
Keystone Symposium on HIV Vaccines: From Basic Research to Clinical Trials, Whistler, British Columbia, Canada, Invited Speaker, 2007.
University of Washington Conjoint Microbiology Module on Virus-Host Interactions, Class Lecture, Seattle, WA, 2007.
University of Washington, Department of Microbiology Seminar, Seattle, WA, 2007.
25th Annual Symposium on Nonhuman Primate Models for AIDS, Monterey, CA, Invited Speaker and Chairperson, 2007.
US-Japan Cooperative Medical Science Program, Monterey, CA, Invited Speaker, 2007.
Mucosal Immunity and HIV/AIDS Vaccines Meeting, Veyrier-du-Lac, France, Invited Speaker, 2007.
HIV/AIDS Research at the National Cancer Institute: a Record of Sustained Excellence, Bethesda, MD, Invited Speaker, 2007.
Gordon Research Conference: The Science of Viral Vectors for Gene Therapy, Ventura, CA, Invited Speaker, 2008.
Institute of Human Virology Seminar, Baltimore, MD, 2008.
Aaron Diamond AIDS Research Center, New York, NY, Seminar, 2008.
George Washington University, Department of Microbiology, Immunology and Tropical Medicine, Washington, D.C., Guest Lecturer, 2008.
6th Annual Vaccines: All Things Considered, GTCbio Conference, Tysons Corner, VA, Invited Speaker, 2008.
French Society for Immunology, Club of Vaccinology, Paris, France, Invited Speaker, 2008.
Symposium: 25 Years After Discovering HIV as the Cause of AIDS, Baltimore, MD, Invited Speaker, 2009
Novartis Vaccines and Diagnostics, Cambridge, MA, Seminar, 2009
AIDS Vaccine 2009; Satellite Session: Replicating Viral Vectors for Use in AIDS Vaccines, Paris, France, Invited Speaker, 2009.
George Washington University, Department of Microbiology, Immunology and Tropical Medicine, Washington, D.C., Guest Lecturer, 2009.
NCI, HIV and AIDS Malignancy Branch Seminar, Bethesda, MD, 2010.

NCI, Center of Excellence in HIV/AIDS and Cancer Virology, Symposium on “New Insights into Mucosal Transmission of HIV/SIV and Its Prevention by Vaccines and Other Modalities, Bethesda, MD, Invited Speaker, 2010.

NIAID, AIDS Vaccine Research Sub-committee, Bethesda, MD, Invited Speaker, 2011.

Europrise Meeting, “Antibodies Beyond Binding”, Strasbourg, France, Invited Speaker, 2011.

Institute of Human Virology, 13th Annual Meeting, Baltimore, MD, Invited Speaker, 2011.

St. Mary’s College of Maryland, St. Mary’s City, MD., 13th Annual Women, Gender and Sexuality Studies Colloquium on HIV/AIDS, Invited Speaker, 2012.

AIDS Vaccine 2012, Satellite Session on Non-neutralizing antibodies: Linking Adaptive and Innate Immunity, Boston, MA, Invited Speaker, 2012.

Viruses Genes and Cancer Symposium, Venice, Italy, Invited Speaker, 2012.

Cent Gardes HIV Vaccine Conference: The B cell response to HIV and HIV vaccines: from broadly neutralizing to non-neutralizing antibodies. Veyrier du Lac, France, Invited Participant, 2012.

HIV Vaccines: Adaptive Immunity and Beyond, Chair-Mucosal Immunity Workshop, Keystone Symposium, Banff, Alberta, CA, March 9-14, 2014.

NCI, Laboratory of Cell Biology Seminar, Bethesda, MD, 2014.

NIAID, DAIDS Workshop: Improving the NHP Model: Variables in Vaginal Transmission and Mucosal Sampling, Bethesda, MD, Invited Speaker, 2014.

Institute of Human Virology, 16th Annual Meeting, Baltimore, MD, Speaker, 2014.

Recent Invited Reviews, Commentaries:

Current Topics in Virology, review chapter, 1999.

Nature Medicine, News and Views commentary, 2000.

Infectious Causes of Cancer: Targets for Intervention, Humana Press, review chapter, 2000.

Pharmacology of HIV Infection and AIDS, OICA International, review chapter, 2000.

DNA and Cell Biology, Frontiers in Molecular Medicine special issue on Viral Regulatory and Accessory Genes for AIDS Vaccine Development, introductory commentary, 2002.

New Generation Vaccines, Third edition, Marcel Dekker, review chapter, 2003.

Current Molecular Medicine Hot Topics issue on HIV Vaccines, review chapter, 2003.

AIDS Reviews, review chapter, 2003.

Expert Review of Vaccines - AIDS Vaccine Supplement review chapter, 2004.

Future HIV Therapy, review chapter, 2007.

Current Opinion in Biotechnology, Review Chapter, 2007.

Expert Opinion on Biological Therapy, Review Chapter, 2008.

International Reviews of Immunology, Review Chapter, 2009.

New Generation Vaccines, 4th Edition, Review Chapter, 2009.

HIV and AIDS, In Tech Review Chapter, 2011.

Current HIV Research, Hot Topic Issue on Fc-Related Immunity and HIV, review chapter, 2013.

Viruses, Special Issue: AIDS Vaccine 2014, review chapter, 2014.

Editorial Boards:

AIDS Research and Human Retroviruses, 1993-Date

Future HIV Therapy, 2006-Date

AIDS Research and Treatment, 2009-2011

Clinical and Vaccine Immunology, 2015-2017

Journal, Program and Grant Review:

Ad-hoc reviewer for: AIDS, AIDS Research and Human Retrovirology, Analytical Biochemistry, Antiviral Research, Blood, BMC Biotechnology, Clinical and Vaccine Immunology, Current HIV Research, Emerging Infectious Diseases, European Journal of Immunology, Expert Review of Vaccines, FASEB Journal, FEBS Letters, Gene Therapy, Immunity, Infection and Immunity, Journal of Acquired Immune Deficiency Syndromes, Journal of Clinical Investigation, Journal of Immunological Methods, Journal of Immunology, Journal of Infectious Diseases, Journal of Leukocyte Biology, Journal of Virology, Microbes and Infection, Molecular Therapy, Mucosal Immunology, Nature Medicine, PLoS ONE, PLoS Pathogens, Proceedings of the National Academy Sciences, U.S.A., Retrovirology, Vaccine, Viral Immunology Virology, Virus Research.

Reviewer for Dept. of Veterans Affairs Merit Review Process

Reviewer for Advanced Technology Program, National Institute of Standards and Technology, US Department of Commerce

Special Emphasis Panel: Integrated Preclinical/Clinical AIDS Vaccine Development Program, NIAID, February, 2004.

Reviewer for Austrian Science Fund, Department for Biological and Medical Sciences

Reviewer for FDA Office of Women's Health 2006 Intramural Scientific Research Program

Reviewer for Bill and Melinda Gates Foundation

Reviewer for French Research Agency (Agence National de la Recherche)

Special Emphasis Panel: Basic HIV Vaccine Discovery Program, NIAID, March, 2010.

Reviewer for Israel Science Foundation

Special Emphasis Panel, HIV Vaccine Research and Design (HIVRAD) Program, NIAID, November, 2011.

Reviewer for Pierre Bergé Endowment Fund, France, 2014.

Committees, Advisory Boards:

1988-1990 - NCI AIDS Vaccine Task Force

1993-1995 - NCI/FCRDC Committee for Review of Chimpanzee Protocols

1996-1998 - OAR AIDS Vaccine Research and Development Coordinating Committee

1996-1998 - Interdepartmental Coordinating Committee on AIDS Vaccine Research and Development, National Office for AIDS Policy

1996-1998 - OAR Vaccine Implementation Group

1997-1998 - Chairperson, Adenovirus Recombinant Vaccine Working Group

1997-1998 - Trans-Agency Chimpanzee Research Committee

1996-1998 - NCI Primate Advisory Committee
 1995-2000 - National Action Plan on Breast Cancer, Breast Cancer Etiology Working Group
 1997-2001 - NIH Biosafety Committee
 1999-2000 - Postdoctoral Fellow Awards Committee
 1999-2001 - NCI, DBS, Promotion Review Panel
 2000-2001 - Vaccines Planning Group for Fiscal Year 2002, Office of AIDS Research
 2000-2001 - NCI, DBS, Promotion Review Panel, Chairperson
 2004-2005 - Advisory Board of The Italian Concerted Action for The Development of a Vaccine against HIV/AIDS
 2005-2006- OAR HIV/AIDS Vaccine Research and Development Planning Workshop for FY 2007
 2007-2008- Advisory Board, ETMAVAC (Env-Tat Mucosal AIDS Vaccine), Seventh Framework Programme, European Union
 2008-2008 - Search Committee, Laboratory of Molecular Biology, CCR, NCI; Tenure Track Investigator
 2005-2011 - Board of Directors, Foundation for Advanced Education in the Sciences, Inc., NIH, Bethesda, MD
 2010-2011- Search Committee, HIV Drug Resistance Program, CCR, NCI; Tenure Track Investigator
 2010-2011- Search Committee, Laboratory of Tumor Immunology and Biology, CCR, NCI; Tenure Track Investigator
 2010-2011- Search Committee, VRC, NIAID Section Head, Tenure Eligible Senior Investigator
 2011-2012 -Earl Stadtman NIH-wide Tenure Track Investigator Search Committee - Immunology
 2011-2012- External Advisory Board, Geovax, Inc. Smyrna, GA
 2008-2012- Central Tenure Committee, NIH
 1998-2012- Interagency Animal Model Committee
 2013-2014-Earl Stadtman NIH-wide Tenure Track Investigator Search Committee - Immunology
 2003-Date - Center for Excellence in Immunology, Steering Committee
 2003-Date - HIV and Cancer Virology Faculty, Steering Committee
 2007-Date- Center of Excellence in HIV/AIDS and Cancer Virology, Steering Committee
 2012-Date- Scientific Advisory Board, Ackerman/Alter Collaboration for AIDS Vaccine Discovery Grant from the Gates Foundation
 2014-Date-NCI Animal Care and Use Committee

Additional Administrative Responsibilities:

Project Officer for Research Support Contracts:

“Support for Research on Retroviral Pathogenesis, Treatment and Prevention”, (N02-RC-91017, 1999-2004; N02-RC-47703, 2004-2009; NO2-RC-2010-00003; 2009-2013).
 “Provision of Animal Facilities and Performance of Routine Experiments and Tests”(N02-RC-97109, 1999-2004; N02-RC-57701, 2005-2013).

“Non-Human Primate Models of AIDS: Prophylactic and Therapeutic Studies,” Part A (N02-RC-17009) 2000-2005.

“Non-Human Primate Models of AIDS: Prophylactic and Therapeutic Studies,” Part B (N02-RC-17100) 2000-2005.

“Provision of Animal Facilities and Performance of Routine Experiments and Test,” (N02-RC-67703, 2005-2013).

Research Interests:

RNA tumor virology.

DNA polymerases of cells and viruses.

Seroepidemiology concerning the role of retroviruses in human diseases.

Immunologic approaches for the diagnosis, treatment and prevention of diseases caused by human retroviruses.

Role of endogenous retroviruses in human disease.

Patents/Licensed Materials:

Broder, S., Matsushita, S., and Robert-Guroff, M.: Therapeutic and diagnostic monoclonal antibody specific for human T-cell leukemia virus type I envelope protein, February, 2, 1988 (U.S. Patent 4,722,888).

Robert-Guroff, M. and Gallo, R.C.: A method for detecting HTLV-III neutralizing antibodies in sera, July 5, 1988 (U.S. Patent 4,755,457).

Biological Material License: B-022-1996/0: Cell line 12/1-2 producing MAB 2A66 against HTLV-II p19.

Robey, F.A., Harris-Kelson, T.A., and Robert-Guroff, M.: Peptomers with enhanced immunogenicity, May 12, 1998 (U.S. Patent 5,750,332).

Lian, L., Srivastava, I.K., Barnett, S.W., Peng, B., Gomez-Roman, V.R., and Robert-Guroff, M.: Combination approaches for generating immune responses against multiple strains selected from a given subtype or serotype. Provisional patent application filed, September 15, 2003; Serial No. 60/504,501.

Peng, B., Voltan, R., Ensoli, B., and Robert-Guroff, M.: Improved replication-competent adenoviral vectors. Patent application filed, November 18, 2005; Serial No. 11/282,319; Licensed, 2005; Issued January 6, 2015 (US Patent No. 8,926,987).

Barnett, S.W., Gomez-Roman, V.R., Robert-Guroff, M., and Srivastava, I.: Combination approaches for generating immune responses. Patent issued: 2007/03394.

BIBLIOGRAPHY

1. Terry, W.D. and Robert, M.S.: Antigenic heterogeneity of human immunoglobulin A proteins. *Science* 153: 1007-1008, 1966.
2. Robert, M. and Gray, I.: Enzymatic mechanisms during temperature acclimation of the blue crab, *Callinectes sapidus*. I. Oxygen consumption and activity of glucose-6-phosphate

- dehydrogenase and 6-phosphogluconate dehydrogenase. Comp. Biochem. Physiol. 42: 377-388, 1972.
3. Robert, M. and Gray, I.: Enzymatic mechanisms during temperature acclimation of the blue crab, *Callinectes sapidus*. II. Kinetic and thermodynamic studies of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. Comp. Biochem. Physiol. 42: 389-400, 1972.
 4. Gallo, R.C., Abrell, J.W., Robert, M.S., Yang, S.S., and Smith, R.G.: Reverse transcriptase from Mason-Pfizer monkey tumor virus, avian myeloblastosis virus and Rauscher leukemia virus and its response to rifamycin derivatives. J. Natl. Cancer Inst. 48: 1185-1189, 1972.
 5. Robert, M.S., Smith, R.G., Gallo, R.C., Sarin, P.S., and Abrell, J.W.: Viral and cellular DNA polymerases: Comparison of activities with synthetic and natural RNA templates. Science 176: 798-800, 1972.
 6. Abrell, J.W., Smith, R.G., Robert, M.S., and Gallo, R.C.: DNA polymerases from RNA tumor viruses and human cells: Inhibition by polyuridylic acid. Science 177: 1111-1114, 1972.
 7. Reitz, M., Gillespie, D., Saxinger, W.C., Robert, M., and Gallo, R.C.: Poly (rA) tracts of tumor virus 70S RNA are not transcribed in endogenous or reconstituted reactions of viral reverse transcriptase. Biochem. Biophys. Res. Commun. 49: 1216-1224, 1972.
 8. Gillespie, D., Takemoto, K., Robert, M., and Gallo, R.C.: Polyadenylic acid in visna virus RNA. Science 179: 1328-1330, 1973.
 9. Gallo, R.C., Sarin, P.S., Wu, A.M., Sarngadharan, M.G., Reitz, M., Robert, M.S., Miller, N., Saxinger, W.C., and Gillespie, D.: On the nature of the nucleic acids and RNA dependent DNA polymerase from RNA tumor viruses and human cells. In Silvestri, L. (Ed.): Possible Episomes in Eukaryotes. Amsterdam, North Holland Publishing, 1973, pp. 14-34.
 10. Falvey, A.K., Kantor, J.A., Robert-Guroff, M.S., Picciano, D.J., Weiss, G.B., Vavich, J.M., and Anderson, W.F.: Mechanism of action of ribonucleic acid directed deoxyribonucleic acid polymerase. I. Transcription of globin messenger ribonucleic acid. J. Biol. Chem. 249: 7049-7056, 1974.
 11. Moroni, C., Robert-Guroff, M., and Martin, D.: Virion and non-virion murine leukemia membrane antigens: Analysis with virus-absorbed antisera. Intervirology 3: 292-304, 1974.
 12. Moroni, C., Schumann, G., Robert-Guroff, M., Suter, E.R., and Martin, D.: Induction of endogenous murine C-type virus in spleen cell cultures treated with mitogens and 5-bromo-2'deoxyuridine. Proc. Natl. Acad. Sci. USA 72: 535-538, 1975.
 13. Robert-Guroff, M., Schrecker, A.W., Brinkman, B.J., and Gallo, R.C.: DNA polymerase γ of human lymphoblasts. Biochemistry 16: 2866-2873, 1977.

14. Robert-Guroff, M. and Gallo, R.C.: Serological analysis of cellular and viral DNA polymerases by an antiserum to DNA polymerase γ of human lymphoblasts. Biochemistry 16: 2874-2880, 1977.
15. Sarngadharan, M.G., Robert-Guroff, M., and Gallo, R.C.: DNA polymerases of normal and neoplastic mammalian cells. Biochim. Biophys. Acta 516: 419-487, 1978.
16. Robert-Guroff, M. and Gallo, R.C.: Type-specific binding antibody to baboon endogenous virus (M7) reverse transcriptase. J. Gen. Virol. 43: 241-246, 1979.
17. Smith, R.G., Nooter, K., Bentvelzen, P., Robert-Guroff, M., Harewood, K., Reitz, M.S., Lee, S.A., and Gallo, R.C.: Characterization of a type-C virus produced by cocultures of human leukemic bone marrow and fetal canine thymus cells. Int. J. Cancer 24: 210-217, 1979.
18. Robert-Guroff, M., Kalyanaraman, V.S., and Sarngadharan, M.G.: Radioimmunoassay for infectious primate retrovirus reverse transcriptase: Characterization, comparison with conventional immunologic assays and applicability to cellular extracts. Int. J. Cancer 25: 749-756, 1980.
19. Posner, L.E., Robert-Guroff, M., Kalyanaraman, V.S., Poiesz, B.J., Ruscetti, F.W., Fossieck, B., Bunn, P.A., Minna, J.D., and Gallo, R.C.: Natural antibodies to the human T-cell lymphoma virus in patients with cutaneous T-cell lymphomas. J. Exp. Med. 154: 333-346, 1981.
20. Robert-Guroff, M., Ruscetti, F.W., Posner, L.E., Poiesz, B.J., and Gallo, R.C.: Detection of the human T-cell lymphoma virus p19 in cells of some patients with cutaneous T-cell lymphoma and leukemia using a monoclonal antibody. J. Exp. Med. 154: 1957-1964, 1981.
21. Gallo, R.C., Popovic, M., Ruscetti, F.W., Wainberg, M.A., Royston, I., Reitz, M.S., Jr., Broder, S., and Robert-Guroff, M.: Interaction of T cell growth factor and a new retrovirus (HTLV) with human T cells. In Marchesti, V.T. and Gallo, R.C. (Eds.): Differentiation and Function of Hematopoietic Cell Surfaces, Vol. I. UCLA Symposia on Molecular and Cellular Biology. New York, Alan R. Liss, 1982, pp. 231-246.
22. Gallo, R.C., Popovic, M., Ruscetti, F.W., Kalyanaraman, V.S., Reitz, M.S., Jr., Royston, I., Broder, S., and Robert-Guroff, M.: Effects of the human T-cell lymphoma (leukemia) virus and T-cell growth factor on human T-cells. In Revoltella, R.P., Pontieri, G.M., Basilico, C., Rovera, G., Gallo, R.C., and Subak-Sharpe, J.H. (Eds.): Expression of Differentiated Functions in Cancer Cells. New York, Raven Press, 1982, pp. 191-205.
23. Robert-Guroff, M., Nakao, Y., Notake, K., Ito, Y., Sliski, A., and Gallo, R.C.: Natural antibodies to the human retrovirus HTLV in a cluster of Japanese patients with adult T-cell leukemia. Science 215: 975-978, 1982.

24. Gallo, R.C., Mann, D., Broder, S., Ruscetti, F.W., Maeda, M., Kalyanaraman, V.S., Robert-Guroff, M., and Reitz, M.S., Jr.: Human T-cell leukemia-lymphoma virus (HTLV) is in T- but not B-lymphocytes from a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 79: 5680-5683, 1982.
25. Blattner, W.A., Kalyanaraman, V.S., Robert-Guroff, M., Lister, T.A., Galton, D.A.G., Sarin, P., Crawford, M.H., Catovsky, D., Greaves, M., and Gallo, R.C.: The human type-C retrovirus, HTLV, in Blacks from the Caribbean and relationship to adult T-cell leukemia/lymphoma. Int. J. Cancer 30: 257-264, 1982.
26. Robert-Guroff, M., Fahey, K.A., Maeda, M., Nakao, Y., Ito, Y., and Gallo, R.C.: Identification of HTLV p19 specific natural human antibodies by competition with monoclonal antibody. Virology 122: 297-305, 1982.
27. Kalyanaraman, V.S., Sarngadharan, M.G., Robert-Guroff, M., Miyoshi, I., Blayney, D., Golde, D., and Gallo, R.C.: A new subtype of human T-cell leukemia/lymphoma virus (HTLV-II) associated with a T-cell variant of Hairy cell leukemia. Science 218: 571-573, 1982.
28. Popovic, M., Reitz, M.S., Jr., Sarngadharan, M.G., Robert-Guroff, M., Kalyanaraman, V.S., Nakao, Y., Miyoshi, I., Minowada, J., Yoshida, M., Ito, Y., and Gallo, R.C.: The virus of Japanese adult T-cell leukemia is a member of the human T-cell leukemia virus group. Nature 300: 63-66, 1982.
29. Gallo, R.C., Robert-Guroff, M., Kalyanaraman, V.S., Ceccherini-Nelli, L., Ruscetti, F.W., Broder, S., Sarngadharan, M.G., Ito, Y., Maeda, M., Wainberg, M., and Reitz, M.S.: Human T-cell retrovirus and adult T-cell lymphoma and leukemia: Possible factors on viral incidence. In Chandra, P. (Ed.): Biochemical and Biological Markers of Neoplastic Transformation. New York, Plenum Press, 1983, pp. 503-513.
30. Blayney, D.W., Jaffe, E.S., Fisher, R.I., Schechter, G.P., Cossman, J., Robert-Guroff, M., Kalyanaraman, V.S., Blattner, W.A., and Gallo, R.C.: The human T-cell leukemia/lymphoma virus (HTLV), lymphoma, lytic bone lesions, and hypercalcemia. Ann. Int. Med. 98: 144-151, 1983.
31. Popovic, M., Sarin, P.S., Robert-Guroff, M., Kalyanaraman, V.S., Mann, D., Minowada, J., and Gallo, R.C.: Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 219: 856-859, 1983.
32. Blattner, W.A., Blayney, D.W., Jaffe, E.S., Robert-Guroff, M., Kalyanaraman, V.S., and Gallo, R.C.: Epidemiology of HTLV associated leukemia. In Neth, R., Gallo, R.C., Greaves, M.F., Moore, M., and Winkler, K. (Eds.): Modern Trends in Human Leukemia V. Berlin, Springer-Verlag, 1983, pp. 148-155.

33. Reitz, M.S., Jr., Mann, D., Clarke, M.F., Kalyanaraman, V.S., Robert-Guroff, M., Popovic, M., and Gallo, R.C.: HTLV is present in a subset of T-cells from an infected patient: Some immunochemical properties of the infected cells. In Neth, R., Gallo, R.C., Greaves, M.F., Moore, M., and Winkler, K. (Eds.): Modern Trends in Human Leukemia, V. Berlin, Springer-Verlag, 1983, pp. 459-461.
34. Sarngadharan, M.G., Schupbach, J., Kalyanaraman, V.S., Robert-Guroff, M., Oroszlan, S., and Gallo, R.C.: Immunological characterization of the natural antibodies to human T-cell leukemia virus in human sera. In Neth, R., Gallo, R.C., Greaves, M.F., Moore, M., and Winkler, K. (Eds.): Modern Trends in Human Leukemia V. Berlin, Springer-Verlag, 1983, pp. 498-503.
35. Ruscetti, F.W., Robert-Guroff, M., Ceccherini Nelli, L., Minowada, J., Popovic, M., and Gallo, R.C.: Persistent *in vitro* infection by human T-cell leukemia-lymphoma virus (HTLV) of normal human T-lymphocytes from blood relatives of patients with HTLV associated mature T-cell neoplasias. Int. J. Cancer 31: 171-180, 1983.
36. Robert-Guroff, M., Kalyanaraman, V.S., Blattner, W.A., Popovic, M., Sarngadharan, M.G., Maeda, M., Blayney, D., Catovsky, D., Bunn, P.A., Shibata, A., Nakao, Y., Ito, Y., Aoki, T., and Gallo, R.C.: Evidence for human T-cell lymphoma-leukemia virus infection of family members of human T-cell lymphoma-leukemia virus-positive T-cell leukemia- lymphoma patients. J. Exp. Med. 157: 248-258, 1983.
37. Reitz, M.S., Jr., Kalyanaraman, V.S., Robert-Guroff, M., Popovic, M., Sarngadharan, M.G., Sarin, P.S., and Gallo, R.C.: Human T-cell leukemia lymphoma virus: The retrovirus of adult T-cell leukemia/ lymphoma. J. Infect. Dis. 147: 399-405, 1983.
38. Blattner, W.A., Blayney, D.W., Robert-Guroff, M., Sarngadharan, M.G., Kalyanaraman, V.S., Sarin, P.S., Jaffe, E.S., and Gallo, R.C.: Epidemiology of human T-cell leukemia/lymphoma virus. J. Infect. Dis. 147: 406-416, 1983.
39. Haynes, B.F., Robert-Guroff, M., Metzgar, R.S., Franchini, G., Kalyanaraman, V.S., Palker, T., and Gallo, R.C.: Monoclonal antibody against human T-cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny. J. Exp. Med. 157: 907-920, 1983.
40. Sarin, P.S., Aoki, T., Shibata, A., Ohnishi, Y., Aoyagi, Y., Miyakoshi, H., Emura, I., Kalyanaraman, V.S., Robert-Guroff, M., Popovic, M., Sarngadharan, M.G., Nowell, P.C., and Gallo, R.C.: High incidence of the human type-C retrovirus (HTLV) in family members of an HTLV-positive Japanese T-cell leukemia patient and indications of a preleukemic state in one member. Proc. Natl. Acad. Sci. USA 80: 2370-2374, 1983.
41. Sarngadharan, M.G., Robert-Guroff, M., Popovic, M., Schupbach, J., Kalyanaraman, V.S., Reitz, M.S., Wong-Staal, F., and Gallo, R.C.: Human T-cell leukemia virus and human

- leukemogenesis. In Harris, C.C. and Autrup, H.N. (Eds.): Human Carcinogenesis. New York, Academic Press, 1983, pp. 679-707.
42. Gallo, R.C., Kalyanaraman, V.S., Sarngadharan, M.G., Sliski, A., Vonderheid, E.C., Maeda, M., Nakao, Y., Yamada, K., Ito, Y., Gutensohn, N., Murphy, S., Bunn, P.A., Jr., Catovsky, D., Greaves, M.F., Blayney, D.W., Blattner, W.A., Jarrett, W.F.H., zur Hausen, H., Seligmann, M., Brouet, J.C., Haynes, B.F., Jegasothy, B.V., Jaffe, E., Cossman, J., Broder, S., Fisher, R.I., Golde, D.W., and Robert-Guroff, M.: Association of the human type-C retrovirus with a subset of adult T-cell cancers. Cancer Res. 43: 3892-3899, 1983.
 43. Blayney, D.W., Jaffe, E.S., Blattner, W.A., Cossman, J., Robert-Guroff, M., Longo, D.L., Bunn, P.A., Jr., and Gallo, R.C.: The human T-cell leukemia/lymphoma virus (HTLV) associated with American adult T-cell leukemia/lymphoma (ATL). Blood 62: 401-405, 1983.
 44. Blayney, D.W., Blattner, W.A., Robert-Guroff, M., Jaffe, E.S., Fisher, R.I., Bunn, P.A., Jr., Patton, M.G., Rarick, H.R., and Gallo, R.C.: The human T-cell leukemia/lymphoma virus in the southeastern United States. JAMA 250: 1048-1052, 1983.
 45. Bunn, P.A., Jr., Schechter, G.P., Jaffe, E., Blayney, D., Young, R.C., Matthews, M.J., Blattner, W., Broder, S., Robert-Guroff, M., and Gallo, R.C.: Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N. Engl. J. Med. 309: 257-264, 1983.
 46. Robert-Guroff, M. and Gallo, R.C.: Establishment of an etiologic relationship between the human T-cell leukemia/lymphoma virus (HTLV) and adult T-cell leukemia. Blut 47: 1-12, 1983.
 47. Blattner, W.A., Gibbs, W.N., Saxinger, C., Robert-Guroff, M., Clark, J., Lofters, W., Hanchard, B., Campbell, M., and Gallo, R.C.: HTLV-associated leukemia/lymphoma in Jamaica. Lancet ii: 61-64, 1983.
 48. Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., Mann, D., Sidhu, G.D., Stahl, R.E., Zolla-Pazner, S., Leibowitch, J., and Popovic, M.: Isolation of human T-cell leukemia virus in acquired immune-deficiency syndrome (AIDS). Science 220: 865-867, 1983.
 49. Vyth-Dreese, F.A., Rumke, P., Robert-Guroff, M., de Lange, G., and Gallo, R.C.: Antibodies against human T-cell leukemia/lymphoma virus (HTLV) and expression of HTLV p19 antigen in relatives of a T-cell leukemia patient originating from Surinam. Int. J. Cancer 32: 337-342, 1983.
 50. Blayney, D.W., Rohatgi, P.K., Hines, W., Robert-Guroff, M., Saxinger, W.C., Blattner, W.A., and Gallo, R.C.: Sarcoidosis and the human T-cell leukemia-lymphoma virus. Ann. Intern. Med. 99: 409, 1983.

51. Reitz, M.S., Jr., Robert-Guroff, M., Kalyanaraman, V.S., Sarngadharan, M.G., Sarin, P., Popovic, M., and Gallo, R.C.: A retrovirus associated with human adult T-cell leukemia-lymphoma. In Magrath, I.T., O'Connor, G.T., and Ramot, B. (Eds.): Pathogenesis of Leukemias and Lymphomas: Environmental Influences. New York, Raven Press, 1984, pp. 331-338.
52. Markham, P.D., Salahuddin, S.Z., Macchi, B., Robert-Guroff, M., and Gallo, R.C.: Transformation of different phenotypic types of human bone marrow T-lymphocytes by HTLV-I. Int. J. Cancer 33: 13-17, 1984.
53. Gallo, R.C., Sarin, P.S., Saxinger, W.C., Robert-Guroff, M., and Wong-Staal, F.: Human *onc* genes, T-cell growth factors (Il-2) and the family of human retroviruses called HTLV. In Ahmad, F., Black, S., Schultz, J., Scott, W.A., and Whelan, W.J. (Eds.): Advances in Gene Technology: Human Genetic Disorders (16th Miami Winter Symposium). Florida, ICSU Press, 1984, pp. 6-11.
54. Aoki, T., Hamada, C., Ohno, S., Miyakoshi, H., Koide, H., Robert-Guroff, M., Ting, R.C., and Gallo, R.C.: Location of human T-cell leukemia virus (HTLV) p19 antigen on virus-producing cells. Int. J. Cancer 33: 161-165, 1984.
55. Robert-Guroff, M., Sarngadharan, M.G., and Gallo, R.C.: T-cell growth factor. In Guroff, G. (Ed.): Growth and Maturation Factors, Vol. 2. New York, John Wiley & Sons, 1984, pp. 267-308.
56. Haynes, B.F., Palker, T.J., Robert-Guroff, M., Kalyanaraman, V.S., Gallo, R.C., Bolognesi, D.P., and Scearce, R.M.: Monoclonal antibodies against human T-cell leukemia-lymphoma virus p19 and p24 internal core proteins: Spectrum of normal tissue reactivity and use as diagnostic probes. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 197-203.
57. Blattner, W.A., Clark, J.W., Gibbs, W.N., Jaffe, E.S., Robert-Guroff, M., Saxinger, W.C., and Gallo, R.C.: Human T-cell leukemia/lymphoma virus: Epidemiology and relationship to human malignancy. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/ Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 267-274.
58. Robert-Guroff, M., Schupbach, J., Blayney, D.W., Kalyanaraman, V.S., Merino, F., Sarngadharan, M.G., Clark, J., Saxinger, W.C., Blattner, W.A., and Gallo, R.C.: Sero-epidemiologic studies on human T-cell leukemia/lymphoma virus, type I. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 285-295.

59. Greaves, M.F., Verbi, W., Tilley, R., Lister, T.A., Robert-Guroff, M., Blattner, W.A., Reitz, M.S., Jr., and Gallo, R.C.: Human T-cell leukemia virus in immigrants to the United Kingdom. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 297-306.
60. Aoki, T., Hamada, C., Ohno, S., Miyakoshi, H., Koide, H., Robert-Guroff, M., Ting, R.C., and Gallo, R.C.: Location of human T-cell leukemia virus (HTLV) p19 and a role of natural antibodies to HTLV in antibody-dependent cell-mediated cytotoxicity of HTLV-producing cells. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 307-312.
61. Saxinger, W.C., Lange-Wantzin, G., Thomsen, K., Lapin, B., Yakovleva, L., Li, L.W., Guo, H.-G., Robert-Guroff, M., Blattner, W.A., Ito, Y., and Gallo, R.C.: Human T-cell leukemia virus: A diverse family of related exogenous retroviruses of humans and Old World primates. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): Human T-Cell Leukemia/Lymphoma Virus. Cold Spring Harbor, Cold Spring Harbor Press, 1984, pp. 323-330.
62. Robert-Guroff, M., Coutinho, R.A., Zadelhoff, A.W., Vyth-Dreese, F.A., and Rumke, P.: Prevalence of HTLV-specific antibodies in Surinam emigrants to the Netherlands. Leuk. Res. 8: 501-504, 1984.
63. Jaffe, E.S., Blattner, W.A., Blayney, D.W., Bunn, P.A., Jr., Cossman, J., Robert-Guroff, M., and Gallo, R.C.: The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Am. J. Surg. Pathol. 8: 263-275, 1984.
64. Greaves, M.F., Verbi, W., Tilley, R., Lister, T.A., Habeshaw, J., Guo, H.-G., Trainor, C.D., Robert-Guroff, M., Blattner, W., Reitz, M., and Gallo, R.C.: Human T-cell leukaemia virus (HTLV) in the United Kingdom. Int. J. Cancer 33: 795-806, 1984.
65. Robert-Guroff, M., Blayney, D.W., Safai, B., Lange, M., Gelmann, E.P., Gutterman, J.W., Mansell, P.W.A., Goedert, J.J., Groopman, J.E., Steigbigel, N.H., Sidhu, G.S., Johnson, J.M., Friedman-Kien, A.E., Downing, R., Bayley, A.C., and Gallo, R.C.: HTLV-I specific antibody in AIDS patients and others at risk. Lancet ii: 128-131, 1984.
66. Merino, F., Robert-Guroff, M., Clark, J., Biondo-Bracho, M., Blattner, W.A., and Gallo, R.C.: Natural antibodies to human T-cell leukemia/lymphoma virus in healthy Venezuelan populations. Int. J. Cancer 34: 501-506, 1984.
67. Gazzolo, L., Gessain, A., Robin, Y., Robert-Guroff, M., and de-The, G.: Antibodies to HTLV-III in Haitian immigrants in French Guiana. N. Engl. J. Med. 311: 1252-1253, 1984.
68. Tsoukas, C., Gervais, F., Shuster, J., Gold, P., O'Shaughnessy, M., and Robert-Guroff, M.: Association of HTLV-III antibodies and cellular immune status of hemophiliacs. N. Engl. J. Med. 311: 1514-1515, 1984.

69. Gessain, A., Gazzolo, L., Yoyo, M., Fortier, L., Robert-Guroff, M., and de The, G.: Sickle cell anemia patients from Martinique have an increased prevalence of HTLV-I antibodies. Lancet ii: 1155-1156, 1984.
70. Blattner, W.A., Robert-Guroff, M., Kalyanaraman, V.S., Sarin, P., Jaffe, E.S., Blayney, D.W., Zener, K.A., and Gallo, R.C.: Preliminary epidemiological observations of a virus-associated with T-cell neoplasm in man. In Magrath, I.T., O'Connor, G.T., and Ramot, B. (Eds.): Pathogenesis of Leukemias and Lymphomas: Environmental Influences. New York, Raven Press, 1984, pp. 339-347.
71. Robert-Guroff, M. and Shepard, E.: A monoclonal antibody defining a 52,000 molecular weight human T-cell leukemia virus-associated glycoprotein expressed by infected cells. J. Virol. 53: 214-220, 1985.
72. Robert-Guroff, M., Markham, P.D., Popovic, M., and Gallo, R.C.: Isolation, characterization, and biological effects of the first human retroviruses: The human T-lymphotropic retrovirus family. In Vogt, P.K. (Ed.): Current Topics in Microbiology and Immunology, Vol. 115. Berlin, Springer-Verlag, 1985, pp. 7-31.
73. Aoki, T., Miyakoshi, H., Koide, H., Yoshida, T., Ishikawa, H., Sugisaki, Y., Mizukoshi, M., Tamura, K., Misawa, H., Hamada, C., Ting, R.C., Robert-Guroff, M., and Gallo, R.C.: Seroepidemiology of human T-lymphotropic retrovirus type I (HTLV-I) in residents of Niigata prefecture, Japan. Int. J. Cancer 35: 301-306, 1985.
74. Weiss, S.H., Goedert, J.J., Sarngadharan, M.G., Bodner, A.J., Biggar, R.J., Clark, J.W., Dodd, R.Y., Gelmann, E.P., Giron, J.A., Greene, M.H., Melbye, M., Popovic, M., Robert-Guroff, M., Saxinger, W.C., Simberkoff, M., Winn, D.M., Gallo, R.C., and Blattner, W.A.: Screening test for HTLV-III (AIDS agent) antibodies: Specificity, sensitivity and applications. JAMA 253: 221-225, 1985.
75. Robert-Guroff, M., Torrey, E.F., and Brown, M.: Retroviruses and schizophrenia. Br. J. Psychiatry 146: 326, 1985.
76. Clark, J.W., Robert-Guroff, M., Ikehara, O., Henzan, E., and Blattner, W.A.: The human T-cell leukemia/lymphoma virus type I in Okinawa. Cancer Res. 45: 2849-2852, 1985.
77. Robert-Guroff, M. and Clark, J.W.: Antigenicity of HTLV-associated gp52: Greater response in leukemia patients compared to healthy donors exposed to the virus. Cancer Res. 45: 3374-3377, 1985.
78. Robert-Guroff, M., Brown, M., and Gallo, R.C.: HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 316: 72-74, 1985.

79. Clark, J., Saxinger, C., Gibbs, W.N., Lofters, W., Lagranade, L., Deceulaer, K., Ensroth, A., Robert-Guroff, M., Gallo, R.C., and Blattner, W.A.: Seroepidemiologic studies of human T-cell leukemia/lymphoma virus type I in Jamaica. Int. J. Cancer 36: 37-41, 1985.
80. Goedert, J.J., Weiss, S.H., Biggar, R.J., Landesman, S.H., Weber, J., Grossman, R.J., and Robert-Guroff, M.: Lesser AIDS and tuberculosis. Lancet ii: 52, 1985.
81. Robert-Guroff, M.: Detection of antibodies to human T cell leukemia virus (HTLV) in AIDS patients and others at risk. In Tashjian, R.J. (Ed.): Equine Infectious Anemia. A National Review of Policies, Programs and Future Objectives. Amarillo, American Quarter House Association, 1985, pp. 122-126.
82. Goldstein, A.L., Naylor, P.H., Schulof, R.S., Simon, G.L., Sztejn, M.B., Kessler, C.M., Robert-Guroff, M., and Gallo, R.C.: Thymosin in the staging and treatment of HTLV-III positive homosexuals and hemophiliacs with AIDS-related immune dysfunction. In Gupta, S. (Ed.): AIDS-Associated Syndromes. New York, Plenum Publishing, 1985, pp. 129-140.
83. Gazzolo, L., Robert-Guroff, M., Jennings, A., DucDodon, M., Najberg, G., Peti, M.P., and de The, G.: Type-I and type-III HTLV antibodies in hospitalized and out-patient Zairians. Int. J. Cancer 36: 373-378, 1985.
84. Abe, T., Kinoshita, T., Matsuda, J., Ryu, T., Ting, R.C., Aoki, T., Robert-Guroff, M., Miyakoshi, H., and Gallo, R.C.: Detection of antibodies to HTLV-I and -III in sera from Japanese hemophiliacs. Cancer Res. 45: 4621s-4623s, 1985.
85. de The, G., Gessain, A., Gazzolo, L., Robert-Guroff, M., Najberg, G., Calender, A., Peti, P., Brubaker, G., Bensliman, A., Fabry, J., Strobel, M., Robin, Y., and Fortune, R.: Comparative seroepidemiology of HTLV-I and HTLV-III in the French West Indies and some African countries. Cancer Res. 45: 4633s-4636s, 1985.
86. Robert-Guroff, M. and Gallo, R.C.: The family of human T-cell lymphotropic type C retroviruses known as HTLV and their role in human T-cell diseases. In Nakamura, R.M. and O'Sullivan, M.B. (Eds.): Clinical Laboratory Molecular Analyses. New York, Grune and Stratton, 1985, pp. 109-127.
87. Gallo, R.C. and Robert-Guroff, M.: The HTLV family of human retroviruses and their association with T-cell suppression. In Nakamura, R.M. and O'Sullivan, M.D. (Eds.): Clinical Laboratory Molecular Analyses. New York, Grune and Stratton, 1985, pp. 257-266.
88. Robert-Guroff, M. and Gallo, R.C.: Human T-cell leukemia (lymphotropic) retroviruses: The HTLV family and their role in leukemias, lymphomas and AIDS. In Gallo, R.C., Stehelin, D., and Varnier, O.E. (Eds.): Retroviruses and Human Pathology. Clifton, Humana Press, 1985, pp. 301-318.

89. Gazzolo, L., DucDodon, M., Gessain, A., Robert-Guroff, M., and de The, G.: RNA viruses and lymphocyte immune functions. In Gallo, R.C., Stehelin, D., and Varnier, O.E. (Eds.): Retroviruses and Human Pathology. Clifton, Humana Press, 1985, pp. 353-361.
90. Blattner, W.A., Clark, J.W., Gibbs, W.N., Williams, C.K.O., Nomura, A., Mann, D., Saxinger, C., Robert-Guroff, M., and Gallo, R.C.: HTLV: Epidemiology and relationship to disease. In Miwa, M. (Ed.): Retroviruses in Human Lymphoma/Leukemia. Tokyo, Japan Sci. Soc. Press, 1985, pp. 93-108.
91. Gallo, R.C., Ratner, L., Popovic, M., Salahuddin, S.Z., Sarnagadharan, M.G., Wong-Staal, F., Shaw, G., Hahn, B., Markham, P.D., Groopman, J., Safai, B., Reitz, M., and Robert-Guroff, M.: The family of human T-lymphotropic retroviruses called human T-cell leukemia/lymphoma virus (HTLV): Their role in lymphoid malignancies and lymphosuppressive disorders (AIDS). In Marks, P.A. (Ed.): Genetics, Cell Differentiation and Cancer. Orlando, Academic Press, 1985, pp. 183-202.
92. Robert-Guroff, M. and Gallo, R.C.: HTLV and leukemia in man. In Gale, R.P. and Golde, D.W. (Eds.): Leukemia: Recent Advances in Biology and Treatment. New York, Alan R. Liss, 1985, pp. 115-136.
93. Hattori, T., Robert-Guroff, M., Chosa, T., Matsuoka, M., Yamaguchi, K., Ishii, T., Gallo, R.C., and Takatsuki, K.: Natural antibodies in sera from Japanese individuals infected with HTLV-I do not recognize HTLV-III. Blood 66: 745-747, 1985.
94. Manzari, V., Gradilone, A., Barillari, G., Zani, M., Collalti, E., Pandolfi, F., DeRossi, G., Liso, V., Babbo, P., Robert-Guroff, M., and Frati, L.: HTLV-I is endemic in southern Italy: Detection of the first infectious cluster in a white population. Int. J. Cancer 36: 557-559, 1985.
95. Robert-Guroff, M., Clark, J., Lanier, A.P., Beckman, G., Melbye, M., Ebbesen, P., Blattner, W.A., and Gallo, R.C.: Prevalence of HTLV-I in arctic regions. Int. J. Cancer 36: 651-655, 1985.
96. Van de Perre, P., Clumeck, N., Crael, M., Nzabihimana, E., Robert-Guroff, M., De Mol, P., Freyens, P., Butzler, J.-P., Gallo, R.C., and Kanyamupira, J.B.: Female prostitutes: A risk group for infection with human T-cell lymphotropic virus type III. Lancet ii: 524-527, 1985.
97. Clumeck, N., Robert-Guroff, M., Van de Perre, P., Jennings, A., Sibomana, J., Demol, P., Cran, S., and Gallo, R.C.: Seroepidemiological studies of HTLV-III antibody prevalence among selected groups of heterosexual Africans. JAMA 254: 2599-2602, 1985.
98. Koprowski, H., De Freitas, E.C., Harper, M., Sandberg-Wollheim, M., Sheremata, W.A., Robert-Guroff, M., Saxinger, W.C., Feinberg, M.B., Wong-Staal, F., and Gallo, R.C.: Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 318: 154-160, 1985.

99. Bartholomew, C., Charles, W., Saxinger, C., Blattner, W., Robert-Guroff, M., Raju, C., Ratan, P., Ince, W., Quamina, D., Basdeo-Maharaj, K., and Gallo, R.C.: Racial and other characteristics of human T cell leukaemia/lymphoma (HTLV-I) and AIDS (HTLV-III) in Trinidad. Br. Med. J. 290: 1243-1246, 1985.
100. Aoki, T., Hamada, C., Ohno, S., Miyakoshi, H., Kaneko, Y., Robert-Guroff, M., Ting, R.C., and Gallo, R.C.: Roles of HTLV-I p19 and natural antibody to HTLV-I in host immune responses. Hematol. Bluttransfus. 29: 342-344, 1985.
101. Gallo, R.C., Sarngadharan, M.G., Popovic, M., Shaw, G.M., Hahn, B., Wong-Staal, F., Robert-Guroff, M., Salahuddin, S.Z., and Markham, P.D.: HTLV-III and the etiology of AIDS. In Ishizaka, K., Kallos, P., Lachmann, P.J., and Waksman, B.H. (Eds.): Progress in Allergy, Vol. 37. Basel, Karger, 1986. pp. 1-45.
102. Robert-Guroff, M. and Gallo, R.C.: Immunology of the human T-cell leukemia/lymphoma (lymphotropic) viruses (the HTLV 'family'). In Herberman, R.B. (Ed.): Cancer Immunology: Innovating Approaches to Therapy. Boston, Martinus Nijhoff, 1986, pp.1-28.
103. Matsushita, S., Robert-Guroff, M., Trepel, J., Cossman, J., Mitsuya, H., and Broder, S.: Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. USA 83: 2672-2676, 1986.
104. Blattner, W.A., Nomura, A., Clark, J.W., Ho, G.Y.F., Nakao, Y., Gallo, R.C., and Robert-Guroff, M.: Modes of transmission and evidence for viral latency from studies of human T-cell lymphotropic virus type I in Japanese migrant populations in Hawaii. Proc. Natl. Acad. Sci. USA 83: 4895-4898, 1986.
105. Schulof, R.S., Simon, G.L., Szein, M.B., Parenti, D.M., DiGioia, R.A., Courtless, J.W., Orenstein, J.M., Kessler, C.M., Kind, P.D., Schlesselman, S., Paxton, H.M., Robert-Guroff, M., Naylor, P.H., and Goldstein, A.L.: Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects. J. Biol. Resp. Modif. 5: 429-443, 1986.
106. Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F., Gallo, R.C., and Moss, B.: Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature 320: 535-537, 1986.
107. Franchini, G., Robert-Guroff, M., Wong-Staal, F., Ghayeb, J., Kato, I., Chang, T.W., and Chang, N.T.: Expression of the protein encoded by the 3' open reading frame of human T-cell lymphotropic virus type III in bacteria: Demonstration of its immunoreactivity with human sera. Proc. Natl. Acad. Sci. USA 255: 5282-5285, 1986.
108. Robert-Guroff, M., Weiss, S.H., Giron, J.A., Jennings, A.M., Ginsburg, H.M., Margolis, I.B., Blattner, W.A., and Gallo, R.C.: Prevalence of antibodies to HTLV-I, -II, and -III, in intravenous drug abusers from an AIDS endemic region. JAMA 255: 3133-3137, 1986.

109. Robert-Guroff, M. and Gallo, R.C.: A virological perspective on the acquired immunodeficiency syndrome. In Cole H.M. and Lundberg, G.D. (Eds.): AIDS: From the Beginning. Chicago, American Medical Association, 1986, pp. XXVII-XXXI.
110. Epstein, L.G., Sharer, L.R., Oleske, J.M., Connor, E.M., Goudsmit, J., Bagdon, L., Robert-Guroff, M., and Koenigsberger, M.R.: Neurologic manifestations of HIV infection in children. Pediatrics 78: 678-687, 1986.
111. Robert-Guroff, M.: Serologic investigations on the human T-lymphotropic virus type III (HTLV-III) and the acquired immunodeficiency syndrome. Jano (In Spanish) 30: 9-14, 1986.
112. Robert-Guroff, M. and Gallo, R.C.: The human T lymphotropic retroviruses and human immune deficiency. In Cinader, B. and Miller, R.G. (Eds.): Progress in Immunology, VI. Orlando, Academic Press, 1986, pp. 538-547.
113. Robert-Guroff, M., Reitz, M.S., Jr., Robey, W.G., and Gallo, R.C.: *In vitro* generation of an HTLV-III variant by neutralizing antibody. J. Immunol. 137: 3306-3309, 1986.
114. Robert-Guroff, M. and Gallo, R.C.: HTLV: The family of human T lymphotropic retroviruses and their role in leukemia and AIDS. In Harris, C.C. (Ed.): Biochemical and Molecular Epidemiology of Cancer. New York, Alan R. Liss, 1986, pp. 293-301.
115. Franchini, G., Robert-Guroff, M., Ghayeb, J., Chang, N.T., and Wong-Staal, F.: Cytoplasmic localization of the HTLV-III 3'*orf* protein in cultured cells. Virology 155: 593-599, 1986.
116. Putney, S.D., Matthews, T.J., Robey, W.G., Lynn, D.L., Robert-Guroff, M., Mueller, W.T., Langlois, A.J., Ghayeb, J., Petteway, S.R., Jr., Weinhold, K.J., Fischinger, P.J., Wong-Staal, F., Gallo, R.C., and Bolognesi, D.P.: HTLV-III/LAV-neutralizing antibodies to an *E. coli*-produced fragment of the virus envelope. Science 234: 392-395, 1986.
117. Esparza, B., Robert-Guroff, M., Blattner, W.A., Merino, F., and Gallo, R.C.: Prevalence of anti-human T-cell leukemia/lymphoma virus type I natural antibodies in blood donors from Spain. Immunologia (In Spanish) 40-41, 1986.
118. Robert-Guroff, M., Achilli, G., Cattaneo, E., and Rondanelli, E.G.: Serologic studies on HTLV-III and AIDS: Methodologic aspects and implications for diagnosis, progression, and prevention of disease. In Rondanelli, E.G. (Ed.): AIDS (in Italian). Padova, Piccin Nuova Libreria, 1987, pp. 60-69.
119. Levine, P.H., Blattner, W.A., Biggar, R.J., Clark, J., Weiss, S., Robert-Guroff, M., and Saxinger, W.C.: Issues in the seroepidemiology of human retroviruses. In Gallo, R.C., Hazeltine, W., and zur Hausen, H. (Eds.): Viruses and Human Cancer. New York, Alan

- R. Liss, 1987, pp. 93-103.
120. Gurgo, C., Robert-Guroff, M., and Gallo, R.C.: An overview of the human T-lymphotropic retroviruses and the role of HTLV-III/LAV in AIDS. Antibiot.Chemother. 38: 1-12, 1987.
 121. Franchini, G., Robert-Guroff, M., Aldovini, A., Kan, N.C., and Wong-Staal, F.: Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: Correlation of antibody prevalence with clinical status. Blood 69: 437-441, 1987.
 122. Robert-Guroff, M., Oleske, J.M., Connor, E.M., Epstein, L.G., Minnefor, A.B., and Gallo, R.C.: Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases. Pediatr. Res. 21: 547-550, 1987.
 123. Robert-Guroff, M., Giardina, P.J., Robey, W.G., Jennings, A.M., Naugle, C.J., Akbar, A.N., Grady, R.W., and Hilgartner, M.W.: HTLV-III neutralizing antibody development in transfusion-dependent sero-positive patients with B-thalassemia. J. Immunol. 138: 3731-3736, 1987.
 124. Hattori, T., Ikematsu, S., Chosa, T., Yamamoto, S., Matsuoka, M., Uchida, T., Fukutake, K., Robert-Guroff, M., and Takatsuki, K.: Anti-HTLV-III and anti-HTLV-I antibodies and T cell subsets in hemophiliacs living in HTLV-I endemic and nonendemic areas of Japan. Acta Haematol. 77: 25-29, 1987.
 125. Hattori, T., Matsuoka, M., Chosa, T., Yoshiki, T., Robert-Guroff, M., and Takatsuki, K.: Expression of the HT462 antigen on fresh leukemic T cells and on cells of HTLV-I infected lines. Leuk. Res. 11: 251-257, 1987.
 126. Putney, S.D., Javaherian, K., Jackson, J., Lynn, D., Rusche, J., Mueller, W.T., Matthews, T., Bolognesi, D., Ghrayeb, J., Chanda, P.K., Robey, W.G., Petteway, S.R., Robert-Guroff, M., Wong-Staal, F., Krohn, K., and Gallo, R.C.: Expression of HTLV-III envelope proteins in *Escherichia coli* and their induction of neutralizing antibodies. Vaccines 87. Cold Spring Harbor, Cold Spring Harbor Press, 1987, pp. 256-259.
 127. Robert-Guroff, M. and Gallo, R.C.: The biology and molecular biology of the human T-lymphotropic retroviruses. AIDS-Forschung 2: 451-455, 1987.
 128. Gibbs, W.N., Lofters, W.S., Campbell, M., Hanchard, M.B., LaGrenade, L., Cranston, B., Hendriks, J., Jaffe, E.S., Saxinger, C., Robert-Guroff, M., Gallo, R.C., Clark, J., and Blattner, W.A.: Non-Hodgkin lymphoma in Jamaica and its relation to adult T-cell leukemia-lymphoma. Ann. Intern. Med. 106: 361-368, 1987.
 129. Gallo, R.C., Robert-Guroff, M., Wong-Staal, F., Reitz, M.S., Jr., Arya, S.K., and Streicher, H.Z.: HTLV-III/LAV and the origin and pathogenesis of AIDS. Int. Arch. Allergy Appl. Immunol. 82: 471-475, 1987.

130. Rusche, J.R., Lynn, D.L., Robert-Guroff, M., Langlois, A.J., Lysterly, H.K., Carson, H., Krohn, K., Ranki, A., Gallo, R.C., Bolognesi, D.P., Putney, S.D., and Matthews, T.J.: Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc. Natl. Acad. Sci. USA 84: 6924-6928, 1987.
131. Putney, S., Rusche, J., Matthews, T., Krohn, K., Carson, H., Lynn, D., Jackson, J., Robey, W.G., Ranki, A., Robert-Guroff, M., Gallo, R.C., and Bolognesi, D.: HIV neutralizing antibodies elicited by recombinant envelope proteins. In Bolognesi, D. (Ed.): Human Retroviruses, Cancer and AIDS. Approaches to Prevention and Therapy. New York, Alan R. Liss, 1988, pp. 149-159.
132. Matsushita, S., Robert-Guroff, M., Rusche, J., Koito, A., Hattori, T., Hoshino, H., Javaherian, K., Takatsuki, K., and Putney, S.: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62: 2107-2114, 1988.
133. Reitz, M.S., Jr., Wilson, C., Naugle, C., Gallo, R.C., and Robert-Guroff, M.: Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54: 57-63, 1988.
134. Levine, P.H., Blattner, W.A., Clark, J., Tarone, R., Maloney, E.M., Murphy, E.M., Gallo, R.C., Robert-Guroff, M., and Saxinger, W.C.: Geographic distribution of HTLV-I and identification of a new high-risk population. Int. J. Cancer 42: 7-12, 1988.
135. Robert-Guroff, M., Goedert, J.J., Naugle, C.J., Jennings, A.M., Blattner, W.A., and Gallo, R.C.: Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6-year prospective study. AIDS Res. Hum. Retroviruses 4: 343-350, 1988.
136. Putney, S.D., Rusche, J.R., Javaherian, K., Petro, J., Lynn, D.L., O'Keeffe, T.J., Grimaila, R., McDanal, C., Bolognesi, D.P., Matthews, T.J., Matsushita, S., Robert-Guroff, M., and Gallo, R.C.: Mapping of the principal HIV neutralizing epitope. In Ginsberg, H., Brown, F., Lerner, R.A., and Chanock, R.M. (Eds.): Vaccines 88. Cold Spring Harbor, Cold Spring Harbor Press, 1988, pp. 253-258.
137. Weinberg, J.B., Spiegel, R.A., Blazey, D.L., Janssen, R.S., Kaplan, J.E., Robert-Guroff, M., Popovic, M., Matthews, T.J., Haynes, B.F., and Palker, T.J.: HTLV-I infection and adult T-cell leukemia: Report of a cluster in North Carolina. Am. J. Med. 85: 51-58, 1988.
138. Reitz, M.S., Jr., Wilson, C., Naugle, C., Gallo, R.C., and Robert-Guroff, M.: Immunoselection of a neutralization-resistant variant of HIV-1. In Compans, R., Helenius, A., and Oldstone, M. (Eds.): Proceedings of the Symposium on the Cell Biology of Virus Entry, Replication and Pathogenesis. New York, Alan R. Liss, 1989, pp. 397-405.

139. Tschachler, E., Robert-Guroff, M., Gallo, R.C., and Reitz, M.S., Jr.: Human T-lymphotropic virus I-infected T cells constitutively express lymphotoxin *in vitro*. Blood 73: 194-201, 1989.
140. Cardoso, E.A., Robert-Guroff, M., Franchini, G., Gartner, S., Moura-Nunes, J.F., Gallo, R.C., and Terrinha, A.M.: Seroprevalence of HTLV-I in Portugal and evidence of double retrovirus infection of a healthy donor. Int. J. Cancer 43: 195-200, 1989.
141. Earl, P.L., Robert-Guroff, M., Matthews, T.J., Krohn, K., London, W.T., and Moss, B.: Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Hum. Retroviruses 5: 23-32, 1989.
142. Robert-Guroff, M. and Gallo, R.C.: The human immunodeficiency virus and the acquired immunodeficiency syndrome. In Feldman, M., Lamb, J., and Owen, M. (Eds.): The T-Cell. New York, John Wiley & Sons, 1989, pp. 409-419.
143. Matsukura, M., Zon, G., Shinozuka, K., Robert-Guroff, M., Shimada, T., Stein, C.A., Mitsuya, H., Wong-Staal, F., Cohen, J.S., and Broder, S.: Regulation of viral expression of human immunodeficiency virus *in vitro* by an antisense phosphorothioate oligodeoxynucleotide against *rev* (*art/trs*) in chronically infected cells. Proc. Natl. Acad. Sci.USA 86: 4244-4248, 1989.
144. Goedert, J.J., Mendez, H., Drummond, J.E., Robert-Guroff, M., Minkoff, H.L., Holman, S., Stevens, R., Rubinstein, A., Blattner, W.A., Willoughby, A., and Landesman, S.H.: Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gp120. Lancet ii: 1351-1354, 1989.
145. Robert-Guroff, M.: Host immune response: Neutralizing antibodies. In Aldovini, A. and Walker, B. (Eds.): Techniques in HIV Research. New York, Stockton Press, 1990, pp. 179-185.
146. Wilson, C., Reitz, M.S., Jr., Aldrich, K., Klasse, P.J., Blomberg, J., Gallo, R.C., and Robert-Guroff, M.: The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J.Virol. 64: 3240-3248, 1990.
147. Robert-Guroff, M., Popovic, M., Gartner, S., Markham, P., Gallo, R.C., and Reitz, M.S.: Structure and expression of *tat*-, *rev*-, and *nef*-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J. Virol. 64: 3391-3398, 1990.
148. Franchini, G., Markham, P., Gard, E., Fargnoli, K., Keubarawa, S., Jagodzinski, L., Robert-Guroff, M., Lusso, P., Ford, G., Wong-Staal, F., and Gallo, R.C.: Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus

- type 2: Evidence of minimal genetic drift and low pathogenetic effects. J. Virol. 64: 4462-4467, 1990.
149. Vujcic, L., Katzenstein, D., Martin, M., Quinnan, G., and Collaborating Laboratories (Bolognesi, D., Deinhardt, F., Gurtler, L., Eberle, J., Folks, T., Byrn, R., Ho, D., Nara, P., Parks, W., Rasheed, S., Robert-Guroff, M., Weiss, R.): International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. AIDS Res. Hum. Retroviruses 6: 847-853, 1990.
 150. Robert-Guroff, M.: HIV-neutralizing antibodies: Epitope identification and significance for future vaccine. Intern. Rev. Immunol. 7: 15-30, 1990.
 151. Robert-Guroff, M. and Gallo, R.C.: The interaction of human T-cell leukemia and human immunodeficiency retroviruses. In Srivastava, R., Ram, B.P., and Tyle, P. (Eds.): Molecular Mechanisms of Immune Regulation. New York, VCH Publishers, 1991, pp. 233-249.
 152. D'Souza, M.P., Durda, P., Hanson, C.V., Milman, G., and Collaborating Investigators: Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: An international collaboration. AIDS 5: 1061-1070, 1991.
 153. Robert-Guroff, M., Aldrich, K., Muldoon, R., Stern, T.L., Bansal, G.P., Matthews, T.J., Markham, P.D., Gallo, R.C., and Franchini, G.: Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J. Virol. 66: 3602-3608, 1992.
 154. Blomberg, J., Robert-Guroff, M., Blattner, W.A., and Pipkorn, R.: Type- and group-specific continuous antigenic determinants of HTLV. Use of synthetic peptides for serotyping of HTLV-I and -II infection. J. Acquir. Immune Defic. Syndr. 5: 294-302, 1992.
 155. Natuk, R.J., Chanda, P.K., Lubeck, M.D., Davis, A.R., Wilhelm, J., Hjorth, R., Wade, M.S., Bhat, B.M., Mizutani, S., Lee, S., Eichberg, J., Gallo, R.C., Hung, P.P., and Robert-Guroff, M.: Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc. Natl. Acad. Sci. USA 89: 7777-7781, 1992.
 156. Robert-Guroff, M., Roilides, E., Muldoon, R., Venzon, D., Husson, R., Marshall, D., Gallo, R.C., and Pizzo, P.A.: Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: Correlation with clinical status and prognostic value. J. Infect. Dis. 167: 538-546, 1993.
 157. Watkins, B.A., Reitz, M.S., Jr., Wilson, C.A., Aldrich, K., Davis, A.E., and Robert-Guroff, M.: Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: Evidence for multiple pathways. J. Virol. 67: 7493-7500, 1993.

158. Klasse, P.J., McKeating, J.A., Schutten, M., Reitz, Jr., M.S., and Robert-Guroff, M.: An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582[Thr]) decreases antibodies to the CD4-binding site. Virology 196: 332-337, 1993.
159. Veronese, F.D., Reitz, M.S., Jr., Gupta, G., Robert-Guroff, M., Boyer-Thompson, C., Louie, A., Gallo, R.C., and Lusso, P.: Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J. Biol. Chem. 268: 25894-24901, 1993.
160. Tartaglia, J., Franchini, G., Robert-Guroff, M., Abimiku, A., Benson, J., Limbach, K., Wills, M., Gallo, R.C., and Paoletti, E.: Highly attenuated poxvirus vector strains, NYVAC and ALVAC, in retrovirus vaccine development. In Robert, O. (Ed.): Huitieme Colloque Des Cent Gardes - 1993 (Proceedings). Paris, Foundation Merieux, 1993, pp. 293-298.
161. Kalyan, N.K., Lee, S-G., Wilhelm, J., Pisano, M.R., Hum, W-T., Hsiao, C-L., Davis, A.R., Eichberg, J.W., Robert-Guroff, M., and Hung, P.P.: Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 12: 753-760, 1994.
162. Robert-Guroff, M., Louie, A., Myagkikh, M., Michaels, F., Kieny, M-P., White-Scharf, M.E., Potts, B., Grogg, D., and Reitz, M.S., Jr.: Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization. J. Virol. 68: 3459-3466, 1994.
163. Abimiku, A.G., Zwandor, A., Gomwalk, N., Kyari, S., Opajobi, S., Ibanga, A., Guyit, R., Idoko, J., Anteyi, J., Kigbu, E., Ekezue, E., Danladi, M., Williams, E., Adeniyi-Jones, S., Robert-Guroff, M., and Gallo, R.C.: HIV-1, not HIV-2, is prevalent in Nigeria: Need for consideration in vaccine plans. Vaccine Res. 3: 101-103, 1994.
164. Veronese, F.D., Reitz, M.S., Jr., Gupta, G., Robert-Guroff, M., Boyer-Thompson, C., Louie, A., Gallo, R.C., and Lusso, P.: Generation of a neutralization escape mutant in vivo by a change in HIV-1 V3 loop local conformation. In Brown, F., Chanock, R.M., Ginsberg, H.S., and Norrby, E. (Eds.): Vaccines 94. Cold Spring Harbor, Cold Spring Harbor Press, 1994, pp. 189-195.
165. Goedert, J.J. and Dublin, S. for the Mothers and Infants Cohort Study and the HIV-1 Perinatal Serology Working Group: Perinatal transmission of HIV type 1: Associations with maternal anti-HIV serological reactivity. AIDS Res. Hum. Retroviruses 10: 1125-1134, 1994.
166. Reitz, M.S., Jr., Hall, L., Robert-Guroff, M., Lautenberger, J., Hahn, B.M., Shaw, G.M., Kong, L.I., Weiss, S.H., Waters, D., Gallo, R.C., and Blattner, W.: Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV-IIIb).

- AIDS Res. Hum. Retroviruses 10: 1143-1155, 1994.
167. Abimiku, A.G., Stern, T.L., Zwandor, A., Markham, P.D., Calef, C., Kyari, S., Saxinger, W.C., Gallo, R.C., Robert-Guroff, M., and Reitz, M.S.: Subgroup G HIV type 1 isolates from Nigeria. AIDS Res. Hum. Retroviruses 10: 1581-1583, 1994.
 168. Natuk, R.J., Davis, A.R., Chanda, P.K., Lubeck, M.D., Chengalvala, M., Murthy, S.C.S., Wade, M.S., Dheer, S.K., Bhat, B.M., Murthy, K.K., Robert-Guroff, M., Mizutani, S., Lee, S-G., Eichberg, J.W., Gallo, R.C., and Hung, P.P.: Adenovirus Vected Vaccines. Dev.Biol. Stand. 82: 71-77, 1994.
 169. Franchini, G., Tartaglia, J., Benson, J., Robert-Guroff, M., Abimiku, A., Paoletti, E., and Gallo, R.C.: NYVAC/ALVAC recombinant vectors as vaccines against HIV-2 and HTLV-I. In Robert, O. (Ed.): Neuvième Colloque Des Cent Gardes - 1994 (Proceedings). Paris, Foundation Merieux, 1994, pp. 267-273.
 170. Stern, T.L., Reitz, M.S., and Robert-Guroff, M.: Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: In vitro selection against cytopathicity highlights gp120-gp41 interactive regions. J. Virol. 69: 860-1867, 1995.
 171. Abimiku, A.G., Franchini, G., Aldrich, K., Myagkikh, M., Markham, P., Gard, E., Gallo, R.C., and Robert-Guroff, M.: Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. AIDS Res. Hum. Retroviruses 11: 383-393, 1995.
 172. Abimiku, A.G., Franchini, G., Tartaglia, J., Aldrich, K., Myagkikh, M., Markham, P.D., Chong, P., Klein, M., Kieny, M.-P., Paoletti, E., Gallo, R.C., and Robert-Guroff, M.: HIV-1 recombinant poxviruses and subunit boosts induce cross-protection against HIV-2 challenge in rhesus monkeys. Nature Med. 1: 321-329, 1995.
 173. Franchini, G., Robert-Guroff, M., Tartaglia, J., Aggarwal, A., Abimiku, A., Benson, J., Markham, P., Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, J., Paoletti, E., and Gallo, R.C.: Highly attenuated HIV-2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11: 909-920, 1995.
 174. Takeda, S., Dorfman, N.A., Robert-Guroff, M., Notkins, A.L., and Rando, R.F.: Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in Escherichia coli. Hybridoma 14: 9-18, 1995.
 175. Robey, F.A., Kelson-Harris, T., Roller, P.P., and Robert-Guroff, M.: A helical epitope in the C4 domain of HIV glycoprotein 120. J. Biol. Chem. 270: 23918-23921, 1995.
 176. Robert-Guroff, M., Stern, T.L., Richardson, E., Giovanella, B.C., and Michaels, F.H.:

- Presence of Mason-Pfizer monkey virus in some stocks of HBL-100 human mammary epithelial cells. J.Natl. Can. Inst. 88: 372-374, 1996.
177. Myagkikh, M., Alipanah, S., Markham, P.D., Tartaglia, J., Paoletti, E., Gallo, R.C., Franchini, G., and Robert-Guroff, M.: Multiple immunizations with attenuated poxvirus HIV-2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses, 12: 985-992, 1996.
178. Robey, F.A., Kelson-Harris, T., Robert-Guroff, M., Batinic, D., Ivanov, B., Lewis, M.S., and Roller, P.P.: A synthetic conformational epitope from the C4 domain of HIV gp120 that binds CD4. J. Biol. Chem., 271: 17990-17995, 1996.
179. Watkins, B.A., Buge, S., Aldrich, K., Davis, A.E., Robinson, J., Reitz, M.S., Jr., and Robert-Guroff, M.: Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J. Virol., 70: 8431-8437, 1996.
180. Lubeck, M.D., Natuk, R.J., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S.C.S., Chanda, P.K., Nigida, S., Markham, P.D., Zolla-Pazner, S., Steimer, K., Wade, M., Reitz, M.S. Jr., Arthur, L.O., Mizutani, S., Davis, A., Hung, P., Gallo, R.C., Eichberg, J., and Robert-Guroff, M.: Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med., 3: 651-658, 1997.
181. Abimiku, A.G., Robert-Guroff, M., Benson, J., Tartaglia, J., Paoletti, E., Markham, P.D., and Franchini, G.: Long-term survival of SIV_{mac251}-infected macaques previously immunized with NYVAC-SIV vaccines. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology, 15 (Suppl.1): S78-S85, 1997.
182. Buge, S.L., Richardson, E., Alipanah, S., Markham, P., Cheng, S., Kalyan, N., Miller, C.J., Lubeck, M., Udem, S., Eldridge, J., and Robert-Guroff, M.: An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71: 8531-8541, 1997.
183. Zolla-Pazner, S., Lubeck, M., Xu, S., Burda, S., Natuk, R.J., Sinangil, F., Steimer, K., Gallo, R.C., Eichberg, J.W., Matthews, T., and Robert-Guroff, M.: Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime/boost vaccine regimen in chimpanzees. J. Virol. 72: 1052-1059, 1998.
184. Benson, J., Chougnat, C., Robert-Guroff, M., Montefiore, D., Markham, P., Shearer, G., Gallo, R.C., Cranage, M., Paoletti, E., Limbach, K., Venzon, D., Tartaglia, J., and Franchini, G.: Recombinant vaccine-induced protection against the highly pathogenic SIV_{mac251}: dependence on route of challenge exposure. J. Virol. 72: 4170-4182, 1998.

185. Robert-Guroff, M., Kaur, H., Patterson, L.J., Leno, M., Conley, A.J., McKenna, P.M., Markham, P.D., Richardson, E., Aldrich, K., Arora, K., Murty, L., Carter, L., Zolla-Pazner, S., and Sinangil, F.: Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J.Virol. 72: 10275-10280, 1998.
186. Leno, M., Carter, L., Venzon, D.J., Romano, J., Markham, P.D., Limbach, K., Tartaglia, J., Paoletti, E., Benson, J., Franchini, G., and Robert-Guroff, M.: CD8⁺ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy. AIDS Res. Hum. Retroviruses. 15: 461-470, 1999.
187. Buge, S.L., Murty, L., Arora, K., Kalyanaraman, V.S., Markham, P.D., Richardson, E.S., Aldrich, K., Patterson, L.J., Miller, C.J., Cheng, S-M., and Robert-Guroff, M.: Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming/gp120 boosting regimen and challenged vaginally with SIVmac251. J.Virol., 73: 7430-7440, 1999. (Erratum: J. Virol., 73: 9692, 1999)
188. Peng, B., and Robert-Guroff, M.: Adenovirus recombinants as vehicles for AIDS vaccine development. Curr. Top. Virology, 1: 45-60, 1999.
189. Robert-Guroff, M.: IgG surfaces as an important component in mucosal protection. Nature Med., 2: 129-130, 2000.
190. Robert-Guroff, M. and Buehring, G.C.: In pursuit of a human breast cancer virus: from mouse to human. In Goedert, J.J., ed., Infectious Causes of Cancer: Targets for Intervention. Humana Press Inc., Totowa, NJ, Humana Press Inc., 2000, pp. 475-487.
191. Leno, M., Kowalski, M., and Robert-Guroff, M.: CD8⁺ T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees. AIDS 14: 893-894, 2000.
192. Margolis, L., Glushakova, S., Chougnet, C., Shearer, G., Markham, P., Robert-Guroff, M., Benveniste, R., Miller, C.J., Cranage, M., Hirsch, V., and Franchini, G.: Replication of simian immunodeficiency virus (SIV) in ex vivo lymph nodes as a means to assess susceptibility of macaques in vivo. Virology, 275: 391-397, 2000.
193. Patterson, L.J., Peng, B., Abimiku, A.G., Aldrich, K., Murty, L., Markham, P.D., Kalyanaraman, V.S., Alvord, W.G., Tartaglia, J., Franchini, G., and Robert-Guroff, M.: Cross-protection in NYVAC-HIV-1 immunized/HIV-2 challenged but not in NYVAC-HIV-2 immunized/SHIV challenged rhesus macaques. AIDS, 14: 2445-2455, 2000.
194. Leno, M., Buge, S.L., Patterson, L.J., and Robert-Guroff, M.: Development of prophylactic vaccines against HIV. In Fuchs, D. and Aruoma, O.I., eds., Pharmacology of HIV Infection and AIDS. OICA International, Saint Lucia, London, 2000, pp. 71-104.

195. Robey, F.A. and Robert-Guroff, M.: A defined conformational epitope from the C4 domain of HIV type1 glycoprotein 120: anti cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells. AIDS Res. Hum. Retroviruses, 17: 533-541, 2001.
196. Patterson, L.J., Robey, F., Muck, A., Van Remoortre, K., Aldrich, K., Richardson, E., Alvord, W.G., Markham, P.D., Cranage, M., and Robert-Guroff, M.: A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge. AIDS Res. Hum. Retroviruses, 17: 837-849, 2001.
197. Peng, B. and Robert-Guroff, M.: Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol. Lett., 78: 195-200, 2001.
198. Patterson, L.J., Prince, G.A., Richardson, E.S., Alvord, W.G., Kalyan, N., and Robert-Guroff, M.: Insertion of HIV-1 genes into Ad4ΔE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology, 292: 107-113, 2002.
199. Peng, B., Voltan, R., Lim, L., Edghill-Smith, Y., Phogat, S., Dimitrov, D.S., Arora, K., Leno, M., Than, S., Woodward, R., Markham, P.D., Cranage, M., and Robert-Guroff, M.: Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J. Virol., 76: 6016-6026, 2002.
200. Edghill-Smith, Y.Y., Aldrich, K., Zhao, J., Pinczewski, J., Kalyanaraman, V.S., Johnson, M., Heyliger, A., Perrin, P.R., Woodward, R., and Robert-Guroff, M.: Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques. J. Med. Primatol., 31: 313-322, 2002.
201. Patterson, L.J., Malkevich, N., Zhao, J., Peng, B., and Robert-Guroff, M.: Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol., 21: 627-635, 2002.
202. Robert-Guroff, M.: HIV regulatory and accessory proteins: New targets for vaccine development. DNA Cell Biol., 21: 597-598, 2002.
203. Nan, X., Peng, B., Hahn, T-W., Richardson, E., Lizonova, A., Kovesdi, I., and Robert-Guroff, M.: Development of an Ad7 cosmid system and generation of an Ad7ΔE1ΔE3HIV_{mn} env/rev recombinant virus. Gene Ther., 10: 326-336, 2003.
204. Voltan, R. and Robert-Guroff, M.: Live recombinant vectors for AIDS vaccine development. Curr. Mol. Med., 3: 273-284, 2003.
205. Malkevitch, N., Patterson, L.J., Aldrich, K., Richardson, E., Alvord, W.G., and Robert-Guroff, M.: A replication competent Ad5hr-SIV recombinant priming/subunit protein

- boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in mamu-A*01 rhesus macaques. J. Immunol., 170: 4281-4289, 2003.
206. Zhao, J., Lou, Y., Pinczewski, J., Malkevitch, N., Aldrich, K., Kalyanaraman, V.S., Venzon, D., Peng, B., Patterson, L.J., Edghill-Smith, Y., Woodward, R., Pavlakis, G.N., and Robert-Guroff, M.: Boosting of SIV-specific cellular immune responses in rhesus macaques by repeated administration of Ad5hr-SIV *env/rev* and Ad5hr-SIV *gag* recombinants. Vaccine, 21: 4022-4035, 2003.
207. Zhao, J. Pinczewski, J., Gomez-Roman, V.R., Venzon, D., Kalyanaraman, V.S., Markham, P.D., Aldrich, K., Moake, M., Montefiori, D.C., Lou, Y., Pavlakis, G.N., and Robert-Guroff, M.: Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV_{mac251} challenge by a replication competent Ad5hr-SIV*env/rev* and Ad5hr-SIV*gag* recombinant priming/gp120 boosting regimen. J. Virol., 77: 8354-8365, 2003.
208. Patterson, L.J., Malkevitch, N., Pinczewski, J., Venzon, D., Lou, Y., Peng, B., Munch, C., Leonard, M., Richardson, E., Aldrich, K., Kalyanaraman, V.S., Pavlakis, G.N., and Robert-Guroff, M.: Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) *env/rev*, *gag*, and/or *nef* vaccines and boosted with SIVgp120. J. Virol., 77: 8607-8620, 2003.
209. Gomez-Roman, V.R. and Robert-Guroff, M.: Adenoviruses as vectors for HIV vaccines. AIDS Reviews, 5: 178-185, 2003.
210. Patterson, L.J., Peng, B., Nan, X., and Robert-Guroff, M.: Live adenovirus recombinants as vaccine vectors. In: Levine, M.M., Kaper, J.B., Rappuoli, R., Liu, M., and Good, M.F., Eds.): New Generation Vaccines, 3rd edition., New York, Marcel Dekker, Inc., 2004, pp. 25-335.
211. Patterson, L.J., Malkevitch, N., Venzon, D., Pinczewski, J., Gomez-Roman, V.R., Wang, L., Kalyanaraman, V.S., Markham, P.D., Robey, F.A., and Robert-Guroff, M.: Protection against mucosal SIV_{mac251} challenge using replicating adenovirus-SIV multi-gene vaccine priming and subunit boosting. J. Virol., 78: 2212-2221, 2004.
212. Malkevitch, N., Rohne, D., Pinczewski, J., Aldrich, K., Kalyanaraman, V.S., Letvin, N.L., and Robert-Guroff, M.: Evaluation of combination DNA/replication competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res. Hum. Retroviruses, 20: 235-244, 2004.
213. Malkevitch, N.V. and Robert-Guroff, M.: A call for replicating vector prime/protein boost strategies in HIV vaccine design. Exp. Rev. Vaccines, Suppl. 3: 89-101, 2004.

214. Edghill-Smith, Y., Bray, M., Whitehouse, C.A., Miller, D., Mucker, E., Manischewitz, J., King, L.R., Robert-Guroff, M., Hryniewicz, A., Venzon, D., Meseda, C., Weir, J., Nalca, A., Livingston, V., Wells, J., Lewis, M.G., Huggins, J., Zwiers, S.H., Golding, H., and Franchini, G.: Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. *J. Infect. Dis.* 191: 372-381, 2005.
215. Gomez-Roman, V.R., Patterson, L.J., Venzon, D., Liewehr, D., Aldrich, K., Florese, R., and Robert-Guroff, M.: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIV_{mac251}. *J. Immunol.* 174: 2185-2189, 2005.
216. Pinczewski, J., Zhao, J., Malkevitch, N., Patterson, L.J., Aldrich, K., Alvord, W.G., and Robert-Guroff, M.: Enhanced immunity and protective efficacy against SIV_{mac251} intrarectal challenge following Ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. *Viral Immunol.*, 18: 236-243, 2005.
217. Rosati, M., von Gegerfelt, A., Roth, P., Alicea, C., Valentin, A., Robert-Guroff, M., Venzon, D., Montefiori, D.C., Markham, P., Felber, B.K., and Pavlakis, G.N.: DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIV mac251 challenge. *J. Virol.* 79: 8480-8492, 2005.
218. Peng, B., Wang, L.R., Gomez-Roman, V.R., Davis-Warren, A., Montefiori, D.C., Kalyanaraman, V.S., Venzon, D., Zhao, J., Kan, E., Rowell, T.J., Murthy, K.K., Srivastava, I., Barnett, S.W., and Robert-Guroff, M.: Replicating rather than non-replicating Adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high titer antibodies. *J. Virol.* 79: 10200-10209, 2005.
219. Zhao, J., Voltan, R., Peng, B., Davis-Warren, A., Kalyanaraman, V.S., Alvord, W.G., Aldrich, K., Bernasconi, D., Butto, S., Cafaro, A., Ensoli, B., and Robert-Guroff, M.: Enhanced cellular immunity to SIV Gag following co-administration of Adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. *Virology* 342: 1-12, 2005.
220. Gomez-Roman, V.R., Florese, R.H., Patterson, L.J., Peng, B., Venzon, D., Aldrich, K., and Robert-Guroff, M.: A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. *J. Immunol. Meth.* 308: 53-67, 2006.
221. Gomez-Roman, V.R., Grimes, G.J., Jr., Potti, G.K., Peng, B., Demberg, T., Gravlin, L., Treece, J., Markham, P.D., and Robert-Guroff, M.: Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV and SHIV-infected rhesus macaques. *Vaccine*, 24: 5064-5072, 2006.
222. Malkevitch, N.V., Patterson, L.J., Aldrich, M.K., Wu, Y., Venzon, D., Florese, R.H., Kalyanaraman, V.S., Pal, R., Lee, E.M., Zhao, J., Cristillo, A., and Robert-Guroff, M.: Durable protection of rhesus macaques immunized with a replicating Adenovirus-SIV

- multigene prime/protein boost vaccine regimen against a second SIV_{mac251} rectal challenge: role of SIV-specific CD8+ T cell responses. Virology, 353: 83-98, 2006.
223. Gomez-Roman, V.R., Florese, R.H., Peng, B., Montefiori, D., Kalyanaraman, V.S. Venzon, D., Srivastava, I., Barnett, S.W., and Robert-Guroff, M.: An adenovirus-based HIV subtype-B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype-B HIV strains. J. Acquir. Immune Defic. Syndr., 43: 270-277, 2006.
224. Florese, R.H., Van Rompay, K.K.A, Aldrich, K., Forthal, D.N., Landucci, G., Mahalanabis, M., Haigwood, N., Venzon, D., Kalyanaraman, V.S., Marthas, M.L., and Robert-Guroff, M.: Evaluation of passively transferred, non-neutralizing ADCC-mediating IgG in protection of neonatal rhesus macaques against oral SIV_{mac251} challenge. J. Immunol., 177: 4028-4036, 2006.
225. Peng, B., Voltan, R., Cristillo, A., Alvord, W.G., Davis-Warren, A., Zhou, Q., Murthy, K.K., and Robert-Guroff, M.: Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS, 20:2149-2157, 2006.
226. Titti, F., Cafaro, A., Ferrantelli, F., Tripiciano, A., Moretti, S., Capato, A., Gavioli, R., Ensoli, F., Robert-Guroff, M., Barnett, S., and Ensoli, B.: Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opinion on Emerging Drugs, 12: 23-48, 2007.
227. Demberg, T., Florese, R.H., Heath, M.J., Larsen, K., Kalisz, I., Kalyanaraman, V.S., Lee, E. M., Pal, R., Venzon, D., Grant, R., Patterson, L.J., Koriath-Schmitz, B., Buzby, A., Dombagoda, D., Montefiori, D.C., Letvin, N.L., Cafaro, A., Ensoli, B., and Robert-Guroff, M.: A replication-competent Adenovirus-human immunodeficiency virus (Ad-HIV) *tat* and Ad-HIV *env* priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV_{89.6P} challenge in rhesus macaques. J. Virol., 81: 3414-3427, 2007.
228. Florese, R.H. and Robert-Guroff, M.: Non-neutralizing antibodies and vaccine-induced protection against HIV. Future HIV Ther. 1: 259-271, 2007.
229. Zhou, Q., Hidajat, R., Peng, B., Venzon, D., Aldrich, M.K., Richardson, E., Lee, E.M. Kalyanaraman, V.S., Grimes, G., Gomez-Roman, V.R., Summers, L.E., Malkevich, N., and Robert-Guroff, M.: Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV_{mac251}. Vaccine, 25: 8021-8035, 2007.
230. Robert-Guroff, M.: Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotech., 18: 546-556, 2007.

231. Patterson, L.J., Beal, J., Demberg, T., Florese, R.H., Malkevich, N., Venzon, D., Aldrich, K., Richardson, E., Kalyanaraman, V.S., Kalisz, I., Lee, E.-M., Montefiori, D.C., Robey, F.A., and Robert-Guroff, M.: Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following SHIV_{89.6P} challenge in *Mamu-A*01* negative rhesus macaques. *Virology*, 374: 322-337, 2008.
232. Florese, R.H., Wiseman, R.W., Venzon, D., Karl, J.A., Demberg, T., Larsen, K., Flanary, L., Kalyanaraman V.S., Pal, R., Titti, F., Patterson, L.J., Heath, M.J., O`Conner, D., Cafaro, A., Ensoli, B., and Robert-Guroff, M.: Comparative study of Tat vaccine regimens in Mauritian cynomologus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV_{89.6P} infection. *Vaccine*, 26: 3312-3321, 2008.
233. Patterson, L.J. and Robert-Guroff, M.: Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. *Expert Opin . Biol. Ther.*, 8: 1347-1363, 2008.
234. Morgan, C., Marthas, M., Miller, C., Duerr, A., Cheng-Mayer, C., Desrosiers, R., Flores, J., Haigwood, N. Hu, S-L., Johnson, R.P., Lifson, J., Montefiori, D., Moore, J., Robert-Guroff, M., Robinson, H., Self, S., and Corey, L.: The use of nonhuman primate models in HIV vaccine development. *PLoS Med.* 5: e173, 2008.
235. Demberg, T., Boyer, J., Malkevich, N., Patterson, L.J., Venzon, D., Summers, E.L., Kalisz, I., Kalyanaraman, V.S., Lee, E.M., Weiner, D.B., and Robert-Guroff, M.: Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating Adenovirus SIV recombinant followed by protein boosting does not control a pathogenic SIV_{mac251} mucosal challenge. *J. Virol.*, 82: 10911-10921, 2008.
236. Bogers, W.M.J.M., Davis, D., Baak, I., Kan, E., Hofman, S., Sun, Y., Mortier, D., Lian, Y., Oostermeijer, H., Fagrouch, Z., Dubbes, R., van der Maas, M., Mooij, P., Koopman, G., Verschoor, E., Langedijk, J.P.M., Zhao, J., Brocca-Cofano, E., Robert-Guroff, M., Srivastava, I., Barnett, S., and Heeney, J.L.: Systemic neutralizing antibodies induced by long-interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. *Virology*, 382: 217-225, 2008.
237. Robert-Guroff, M., Nabel, G.J., and Shiver, J.W.: Replication-defective and competent adenovirus recombinants as vaccine vectors. In: *New Generation Vaccines*, 4th Edition, M. M. Levine, G. Dougan, M.F. Good, M.A. Liu, G.J. Nabel, J.P. Nataro, and R. Rappuoli, eds., Informa Healthcare, New York. pp. 352-360, 2009.
238. Hidajat, R., Xiao, P., Zhou, Q., Venzon, D., Summers, L.E., Kalyanaraman, V.S. Montefiori, D.C., and Robert-Guroff, M.: Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal SIV_{mac251} challenge of rhesus macaques. *J. Virol.*, 83: 791-801, 2009.

239. Demberg, T. and Robert-Guroff, M.: Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol., 28: 20-48, 2009.
240. Florese, R.H., Demberg, T., Xiao, P., Kuller, L., Larsen, K., Summers, L.E., Venzon, D., Cafaro, A., Ensoli, B., and Robert-Guroff, M.: Contribution of non-neutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared to multigenic vaccines. J. Immunol., 182: 3718-3727, 2009.
241. Hidajat, R., Kuate, S., Venzon, D., Kalyanaraman, V., Kalisz, I., Treece, J., Lian, Y., Barnett, S.W., and Robert-Guroff, M.: Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine, 28: 3963-3971, 2010.
242. Patel, V., Valentin, A., Kulkarni, V., Rosati, M., Bergamaschi, C., Jalah, R., Alicea, C., Minang, J., Trivett, M., Ohlen, C., Zhao, J., Robert-Guroff, M., Khan, A., Draghia-Akli, R., Felber, B., and Pavlakis, G.: Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine, 28: 4827-4836, 2010.
243. Xiao, P., Zhao, J., Patterson, L.J., Brocca-Cofano, E., Venzon, D., Kozlowski, P.A., Hidajat, R., Demberg, T., and Robert-Guroff, M.: Multiple vaccine-elicited non-neutralizing anti-envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV_{89.69} challenge in rhesus macaques. J. Virol., 84: 7161-7173, 2010. (Selected for Faculty of 1000 Medicine: <http://f1000medicine.com/article/id/3548977/evaluation>)
244. Cafaro, A., Bellino, S., Titti, F., Maggiorella, M.T., Sernicola, L., Wiseman, R.W., Venzon, D., Karl, J.A., O'Connor, D., Monini, P., Robert-Guroff, M., and Ensoli, B.: Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J. Virol., 84: 8953-8958, 2010.
245. Palermo, R.E., Patterson, L.J., Aicher, L.D., Korth, M.J., Robert-Guroff, M., and Katze, M.G.: Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J. Virol., 85: 1099-1116, 2011.
246. George, J., Brocca Cofano, E., Lybarger, E., Louder, M., Lafont, B.A., Mascola, J.R., Robert-Guroff, M., and Mattapallil, J.J.: Early short-term anti-retroviral therapy is associated with a reduced prevalence of CD8⁺FoxP3⁺ T cells in SIV infected controller rhesus macaques. AIDS Res. Hum. Retroviruses, 27: 763-775, 2011.

247. Patterson, L.J., Daltabuit-Test, M., Xiao, P., Zhao, J., Hu, W., Wille-Reece, U., Brocca-Cofano, E., Kalyanaraman, V.S., Kalisz, I., Whitney, S., Lee, E.M., Pal, R., Montefiori, D.C., Dandekar, S., Seder, R., Roederer, M., Wiseman, R.W., Hirsch, V., and Robert-Guroff, M.: Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. *Virology*, 411: 87-102, 2011.
248. Brocca-Cofano, E., McKinnon, K., Demberg, T., Venzon, D., Hidajat, R., Xiao, P., Daltabuit-Test, M., Patterson, L.J., and Robert-Guroff, M.: Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. *Vaccine*, 29: 3310-3319, 2011.
249. Brocca-Cofano, E., Xiao, P., and Robert-Guroff, M.: HIV Envelope specific antibody and vaccine efficacy. In: *HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies*, N. Dumais (Ed.), ISBN: 978-953-307-665-2, In Tech, pp. 257-280, 2011. Available from: http://www.intechopen.com/articles/show_title/hiv-envelope-specific-antibody-and-vaccine-efficacy.
250. Lakhashe, S.K., Velu, V., Sciaranghella, G., Siddappa, N.B., DiPasquale, J.M., Hemashettar, G., Yoon, J.K., Rasmussen, R.A., Yang, F., Lee, S.J., Montefiori, D.C., Novembre, F.J., Villinger, F., Amara, R.R., Kahn, M., Hu, S.L., Li, S., Li, Z., Frankel, F.R., Robert-Guroff, M., Johnson, W.E., Lieberman, J., and Ruprecht, R.M.: Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. *Vaccine*, 29: 5611-5622, 2011.
251. Demberg, T., Ettinger, A.C., Aladi, S., McKinnon, K., Kuddo, T., Venzon, D., Patterson, L.J., Phillips, T.M., and Robert-Guroff, M.: Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. *Vaccine*, 29: 6017-6028, 2011.
252. Vargas-Inchaustegui, D.A., Demberg, T., and Robert-Guroff, M.: A CD8 α ⁻ subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and independent cytotoxic activities. *Immunology*, 134: 326-340, 2011.
253. Fenizia, C., Keele, B., Nichols, D., Cornara, S., Binello, N., Vaccari, M., Pegu, P., Robert-Guroff, M., Ma, Z.M., Miller, C.J., Venzon, D., Hirsch, V., and Franchini, G.: TRIM5 α does not affect simian immunodeficiency virus SIV_{mac251} replication in vaccinated or unvaccinated Indian Rhesus Macaques following intrarectal challenge exposure *J. Virol.*, 85: 12399-12409, 2011.
254. Bialuk, J., Whitney, S., Andresen, V., Florese, R.H., Nacsa, J., Cecchinato, V., Valeri, V.W., Heraud, J.M., Gordon, S., Parks, R.W., Montefiori, D.C., Venzon, D., Demberg, T., Robert-Guroff, M., Landucci, G., Forthal, D.N. and Franchini, G.: Vaccine induced

- antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. *Vaccine*, 30: 78-94, 2011.
255. Rasmussen, R.A., Siddappa, N.B., Lakhashe, S., Watkins, J., Villinger, F., Ibegbu, C., Florese, R.H., Robert-Guroff, M., Montefiori, D.C., Forthal, D.N., O'Connor, D., and Ruprecht, R.M. for the Clade C Program Project Group: High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. *AIDS*, 26: 149-155, 2012.
256. Qureshi, H., Ma, Z.M., Huang, Y., Hodge, G., Thomas, M.A., DiPasquale, J., DeSilva, V., Fritts, L., Bett, A.J., Casimiro, D., Shiver, J.W., Robert-Guroff, M., Robertson, M.N., McChesney, M.B., Gilbert, P.B., and Miller, C.J.: Low dose penile SIV_{mac251} exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the Phase IIb Step trial of a similar HIV-1 vaccine. *J.Virol.*, 86: 2239-2250, 2012.
257. Gordon, S.N., Kines, R.C., Kutsyna, G., Ma, Z.M., Hryniewicz, A., Roberts, J.N., Fenizia, C., Hidajat, R., Brocca-Cofano, E., Cuburu, N., Buck, C.B., Bernardo, M.L., Robert-Guroff, M., Miller, C.J., Graham, B.S., Lowy, D.R., Schiller, J.T., and Franchini, G.: Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. *J.Immunol.*, 188: 714-723, 2012.
258. Xiao, P., Patterson, L.J., Kuate, S., Brocca-Cofano, E., Thomas, M.A., Venzon, D., Zhao, J., DiPasquale, J., Fenizia, C., Lee, E.M., Kalisz, I., Kalyanaraman, V.S., Pal, R., Montefiori, D., Keele, B.F., and Robert-Guroff, M.: Replicating adenovirus-SIV recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low dose rectal SIV_{mac251} challenge. *J. Virol.*, 86: 4644-4657, 2012.
259. Patterson, L.J., Kuate, S., Daltabuit-Test, M., Li, Q., Xiao, P., McKinnon, K., DiPasquale, J., Cristillo, A.D., Venzon, D., Haase, A., and Robert-Guroff, M.: Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. *Clin. Vac. Immunol.*, 19: 629-637, 2012.
260. Vargas-Inchaustegui, D.A., Xiao, P., Tuero, I., Patterson, L.J., and Robert-Guroff, M.: NK and CD4⁺ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. *J. Immunol.*, 189: 1878-1885, 2012.
261. Demberg, T. and Robert-Guroff, M.: Controlling the HIV/AIDS epidemic: current status and global challenges. *Front. Immunol.*, 3: 250, 2012.
262. Demberg, T., Brocca-Cofano, E., Xiao, P., Venzon, D., Vargas-Inchaustegui, D.A., Lee, E. M., Kalisz, I., Kalyanaraman, V.S., DiPasquale, J., McKinnon, K., and Robert-Guroff, M.:

- Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. *J. Virol.*, 86: 12591-12604, 2012.
263. Vaccari, M., Halwani, R., Patterson, J., Boasso, A., Beal, J., Tryniszewska, E., Hryniewicz, A., Venzon, D., Haddad, E., El-Far, M., Rosati, M., Pavlakis, G., Felber, B., Al-Muhsen, S., Robert-Guroff, M., Sekaly, R.P., and Franchini, G.: Antibodies to gp120 and PD-1 Expression on Virus-Specific CD8+ T-cells in Protection from simian AIDS. *J.Virol.*, 87: 3526-3537, 2013.
264. Demberg, T., Brocca-Cofano, E., Kuate, S., Aladi, S., Vargas-Inchaustegui, D.A., Venzon, D., Kalisz, I., Kalyanaraman, V.S., Lee, E. M., Pal, R., DiPasquale, J., Ruprecht, R., Montefiori, D.C., Srivastava, I., Barnett, S.W., and Robert-Guroff, M.: Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. *Virology*, 440: 210-221, 2013.
265. Vargas-Inchaustegui, D.A. and Robert-Guroff, M.: Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. *Curr. HIV Res.*, 11: 407-420, 2013.
266. Campbell, C.T., Llewellyn, S.R., Demberg, T., Morgan, I.L., Robert-Guroff, M., and Gildersleeve, J.C.: High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge. *PLoS ONE*, 8: e75302, 2013.
267. Thomas, M.A., Song, R., Demberg, T., Vargas-Inchaustegui, D.A., and Robert-Guroff, M.: Effects of the deletion of early region 4 (*E4*) open reading frame 1 (*orf1*), *orf1-2*, *orf1-3* and *orf1-4* on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. *PLoS ONE*, 8: e76344, 2013.
268. Vargas-Inchaustegui, D.A., Xiao, P., Hogg, A.E., Demberg, T., McKinnon, K., Venzon, D., Brocca-Cofano, E., DiPasquale, J., Lee, E.M., Hudacik, L., Pal, R., Sui, Y., Berzofsky, J.A., Liu, L., Langermann, S., and Robert-Guroff, M.: Immune targeting of PD-1^{hi} expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. *Virology*, 447: 274-284, 2013.
269. Thomas, M.A., Demberg, T., Vargas-Inchaustegui, D.A., Xiao, P., Tuero, I., Venzon, D., Weiss, D., Treece, J., and Robert-Guroff, M.: Rhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures. *Vaccine*, 32: 872-880, 2014.
270. Sholukh, A.M., Siddappa, N.B., Shanmuganathan, V., Hemashettar, G., Lakhashe, S.K., Rasmussen, R.A., Watkins, J.D., Vyas, H.K., Thorat, S., Brandstoetter, T., Mukhtar, M.M., Yoon, J.K., Novembre, F.J., Villinger, F., Landucci, G., Forthal, D.N., Ratcliffe, S., Tuero, I., Robert-Guroff, M., Polonis, V.R., Bilska, M., Montefiori, D.C., Johnson, W.E., Ertl, H.C., and Ruprecht, R.M.: Passive immunization of macaques with polyclonal anti-SHIV

- IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. *Retrovirology*, 11: 8, 2014.
271. Moniuszko, M., Liyanage, N.P.M., Doster, M., Parks, R.W., Grubczak, K., Lipinska, D., McKinnon, K., Brown, C., Hirsch, V., Vaccari, M., Gordon, S., Pegu, P., Fenizia, C., Flisiak, R., Grzeszczuk, A., Dabrowska, M., Robert-Guroff, M., Silvestri, G., Stevenson, M., McCune, J., and Franchini, G.: Glucocorticoid treatment at moderate doses of SIV_{mac251}-infected Rhesus macaques decreases the frequency of circulating CD14⁺ CD16⁺⁺ monocytes but does not alter the tissue virus reservoir. *AIDS Res Hum Retroviruses*, 31: 115-126, 2015.
 272. Demberg, T., Mohanram, V., Venzon, D., and Robert-Guroff, M.: Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. *Clin. Immunol.*, 153: 264-276, 2014.
 273. Vargas-Inchaustegui, D.A., Tuero, I., Mohanram, V., Musich, T., Pegu, P., Valentin, A., Sui, Y., Rosati, M., Bear, J., Venzon, D.J., Kulkarni, V., Alicea, C., Pilkington, G.R., Liyanage, N.P.M., Demberg, T., Gordon, S.N., Wang, Y., Hogg, A.E., Frey, B., Patterson, L.J., DiPasquale, J., Montefiori, D.C., Sardesai, N.Y., Reed, S.G., Berzofsky, J.A., Franchini, G., Felber, B.K., Pavlakis, G.N., and Robert-Guroff, M.: Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggest novel combinatorial approaches for enhancing responses. *Clin. Immunol.*, 153: 308-322, 2014.
 274. Mohanram, V., Demberg, T., Tuero, I., Vargas-Inchaustegui, D.A., Pavlakis, G.N., Felber, B.K., and Robert-Guroff, M.: Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques. *J. Immunol. Meth.* 412: 78-84, 2014.
 275. Tuero, I. and Robert-Guroff, M.: Challenges in mucosal HIV vaccine development: Lessons from non-human primate models. *Viruses*, 6: 3129-3158, 2014.
 276. Qureshi, H., Genesca, M., Fritts, L., McChesney, M., Robert-Guroff, M., Miller, C.J.: Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4⁺ T cell activation in rhesus macaques. *PLoS One*, 9: e106004, 2014.
 277. Lakhashe, S.K., Byrareddy, S.N., Zhou, M., Bachler, B. C., Hemashettar, G., Hu, S.L., Villinger, F., Else, J.G., Stock, S., Lee, S.J., Vargas-Inchaustegui, D.A., Brocca Cofano, E., Robert-Guroff, M., Johnson, W.E., Polonis, V.R., Forthal, D.N., Loret, E.P., Rasmussen, R.A., and Ruprecht, R.M.: Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. *Vaccine*, 32: 6527-6536, 2014.
 278. Valentin, A., McKinnon, K., Li, J., Rosati, M., Kulkarni, V., Pilkington, G.R., Bear, J., Alicea, C., Vargas-Inchaustegui, D.A., Patterson, L.J., Pegu, P., Liyanage, P.M., Gordon, S.N., Vaccari, M., Wang, Y., Hogg, A.E., Frey, B., Sui, Y., Reed, S.G., Sardesai, N.Y., Berzofsky, J.A., Franchini, G., Robert-Guroff, M., Felber, B.K., and Pavlakis, G.N.: Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. *Clin. Immunol.*, 155: 91-107, 2014.

279. Thomas, M.A., Tuero, I., Demberg, T., Vargas-Inchaustegui, D.A., Musich, T., Xiao, P., Venzon, D., Labranche, C., Montefiori, D.C., DiPasquale, J., Reed, S.G., DeVico, A., Fouts, T., Lewis, G.K., Gallo, R.C., and Robert-Guroff, M.: HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. *Virology*, 471-473: 81-92, 2014.
280. Gordon, S.N., Doster, M.N. Kines, R.C., Keele, B.F., Brocca Cofano, E., Guan, Y., Pegu, P., Liyanage, N.P.M., Vaccari, M., Cuburu, N., Buck, C.B., Ferrari, G., Montefiori, D., Piatak, Jr., M., Lifson, J.D., Xenophontos, A.M., Venzon, D., Robert-Guroff, M., Graham, B.S. Lowy, D.R., Schiller, J.T., and Franchini, G.: Antibody to the gp120 V1/V2 Loops and CD4⁺ and CD8⁺ T Cell Responses in Protection from SIV_{mac251} Vaginal Acquisition and Persistent Viremia. *J. Immunol.*, 193: 6172-6183, 2014.
281. Vargas-Inchaustegui, D.A., Xiao, P., Demberg, T., Pal, R., and Robert-Guroff, M.: Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T cell-dependent NK cell effector responses in chronically infected rhesus macaques. *Immunology*, in press.